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Background: Non-alcoholic fatty liver disease (NAFLD) is a condition characterised 
by a synergistic association between insulin resistance, obesity and ectopic fat. This 
disease state has an increased prevalence of type Π diabetes (T2DM) and 
cardiovascular disease (CVD), thought to be mediated by the insulin resistance. 
There is much evidence to support the hypothesis that mitochondrial function in 
skeletal muscle may be implicated in the development of insulin resistance and 
obesity. We aim to determine if mitochondrial dysfunction contributes to ectopic fat 
accumulation and the associated metabolic syndrome by altering the post-prandial 
energy storage. 
Methods: To test this hypothesis, we performed a cross sectional study of 17 patients 
with NAFLD and 18 controls. Baseline biochemistry, lipid profile, liver function 
tests (LFT’s) glucose and insulin levels were assessed. Measurement of insulin 
resistance was made using HOMA-IR. Assessment of body composition was 
measured using Tanita bio-impedance analysis (Tanita BC 420, Dolby Medical 
Stirling, UK). Magnetic Resonance Imaging (MRI) and 
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H-Magnetic Resonance 
Spectroscopy (MRS) determined abdominal, visceral, subcutaneous, skeletal muscle 
and intra hepatic fat respectively. We measured mitochondrial function within the 
quadriceps muscle during the study by measuring Phosphocreatine (PCr) recovery 
kinetics using 31P MRS. This analysis was carried out in the NAFLD group and 
compared to healthy controls  
Results: Patients with NAFLD matched with control subjects for age, BMI and 
VO2max had evidence of ectopic fat (higher LF and VAT). Despite this no difference 
in mitochondrial function was apparent.  
Conclusions: Altered skeletal muscle mitochondrial function does not explain 
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1.1 Non-alcoholic fatty liver disease (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic 
liver disease in the general population and is said to be present when fatty liver 
infiltration affects >5% of hepatocytes, in individuals with a history of alcohol 
consumption <14 units a week for females and <21 units for males, without evidence 
of other causes of liver disease such as hepatitis and Wilsons disease. NAFLD is a 
progressive condition and represents a spectrum of varying severity of liver disease, 
ranging from simple steatosis to co-existent inflammation with hepatocyte ballooning 
and necrosis, variable grades of fibrosis, and ultimately cirrhosis and increased risk 
of hepatocellular carcinoma. Non-alcoholic steatohepatitis (NASH) represents the 
more advanced stages of the disease, i.e. the inflammatory component in addition to 
steatosis, which carries a higher risk of cardiovascular disease (CVD) and mortality. 
Approximately 10-25% of patients with NAFLD are said to develop NASH. The 
factors responsible for this change from steatosis to steatohepatitis has been the 
subject of extensive investigation and speculation, but currently the pathphysiology 
of this switch remains elusive (Day & James, 1998b). 
 
Although the pathogenesis of NAFLD is not yet fully understood, much progress has 
been made in recent years in understanding the mechanisms of progression from 
steatosis to more advanced liver inflammation and fibrosis. The disease is mostly 
silent and is often discovered through incidentally elevated liver enzyme levels. It is 
strongly associated with obesity and insulin resistance and is currently considered by 
many as the hepatic component of the metabolic syndrome (Cortez-Pinto & Camilo, 
2004; Niaz et al., 2011). Because NAFLD resembles alcoholic liver disease but 
occurs in people who drink little or no alcohol, excessive daily alcohol consumption 
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must be ruled out before making the diagnosis. Numerous other conditions leading to 
fatty liver must be excluded by history, physical examination, and appropriate 
testing. The most common symptoms that brings NAFLD to medical attention are 
malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort, however 
fatty liver disease rarely results in symptoms until the disease is far advanced so 
hepatomegaly, abnormal enlargement of the liver is also a frequent finding. Serum 
asparate transaminase (AST) and alanine transaminase (ALT) are elevated in almost 
90% of patients (Lavine & Schwimmer, 2004). The AST/ALT ratio is usually less 
than 1; this is much lower than the ratio in alcoholic hepatitis, which is usually above 
2  (Sorbi et al., 1999). NAFLD is more likely to develop in individuals who are 
obese or overweight, and also in type two diabetes (T2D) due to an increased uptake 
of fat in the liver (Mirza, 2011). 
 
Non-alcoholic fatty liver disease affects up to a third of the population worldwide 
and is thought to carry an increased risk of cardio metabolic risk with altered 
cardiovascular outcomes independent of traditional cardiovascular risk factors and 
the metabolic syndrome. It is almost universally characterized by insulin resistance 
and is strongly associated with obesity and T2D (Petersen et al., 2003).  
 
Day and James proposed a “two hit” model in an attempt to provide a 
pathophysiological rationale for the progression of damage to the liver. It is thought 
that the reversible intracellular deposition of triacylglycerols, first hit, leads to 
metabolic and molecular alterations that sensitize the liver to the second hit, this is in 
general referred to as due to oxidative damage and cytokine induced liver injury. 
This two hit theory provides a framework to revise the main mechanisms involved in 
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the pathogenesis of hepatic steatosis and its progression to steatohepatitis 
(Burkhalter, 1996). 
 
A number of radiological modalities can be used in order to detect the presence of fat 
in the liver, however there is no method available that can differentiate between the 
histological subtypes from non-alcoholic hepatic steatosis which is relatively benign 
to the more aggressive NASH (Schwenzer et al., 2009). The use of ultrasound 
scanning can reveal an echo bright liver due to diffuse fatty liver infiltration, but this 
finding can be nonspecific and therefore cannot be used to aid the diagnosis of 
NAFLD. The use of Fibroscan ultrasound (transient elastography) however is more 
specific as this gives a number representing the stiffness of the liver and is therefore 
used in some centres as a diagnostic tool. The use of CT and MRI whilst able to 
identify steatosis lack the sensitivity to detect liver inflammation or more advanced 
fibrosis. Magnetic resonance spectroscopy (MRS) has advantages over other imaging 
methods such as CT, MRI and ultrasound as this method facilitates the acquisition of 
quantitative data rather than qualitative or semi quantitative (Rofsky & Fleishaker, 
1995). In suspected NAFLD, the indications for the use of liver biopsy whilst 
remaining controversial, is the only way to distinguish between simple steatosis 
steatohepatitis and fibrosis. However as there is no specific treatment other than 
weight management for NAFLD such an invasive procedure as liver biopsy may not 
be of clinical benefit, and performing this may not outweigh the associated risks. For 
this reason MRS was used within this study to enable quantification of liver fat as a 






Obesity is generally defined as a condition in which an individual has a body mass 
index (BMI) ≥30kg/m
2 
(Evans & Colls, 2009). The BMI being a measure of the 
relationship between an individual’s weight and height. The medical significance in 
determining BMI is that this describes the body weight relative to height and BMI 
has been found to correlate with total body fat content in adults (Bhaskaran et al., 
2013). A limitation of this measure is that within certain groups for example body 
builders who have larger muscle masses; a higher BMI does not correlate with 
increased fat content. Worldwide obesity is approaching epidemic proportions in the 
US and many other industrialized countries. In the US the prevalence of obesity now 
exceeds 30% of the population and represents the highest rate of obesity worldwide 
(Flegal et al., 2012). Obesity and insulin resistance are both key features of the 
metabolic syndrome and are strongly associated with NAFLD (Gallagher et al., 
2010). 
 
1.3 Ectopic Fat 
The distribution of adipose tissue appears to affect its role in metabolic syndrome. 
Fat that is visceral or intra-abdominal correlates with inflammation, whereas 
subcutaneous fat does not. There are a number of potential explanations for this, 
including experimental observations that omental fat is more resistant to insulin and 
may result in a higher concentration of toxic free fatty acids in the portal circulation 
(Turkoglu et al., 2003). Abdominal fat is known to produce potentially harmful 
levels of cytokines, such as tumour necrosis factor, adiponectin, leptin, resistin, and 




NAFLD is a marker of ectopic fat accumulation combined with a low-grade chronic 
inflammatory state. This results in a number of processes including abnormal 
glucose, fatty acid and lipoprotein metabolism, increased oxidative stress, deranged 
adipokine profile, increased coaguloability of blood, endothelial dysfunction, and an 
accelerated progression of atherosclerosis (Solomon et al., 2008). 
 
A high proportion of NAFLD patients display features of the metabolic syndrome 
and there is evidence linking NAFLD to increased cardiovascular disease risk over 
and above that associated with the metabolic syndrome. This suggests that NAFLD 
may contribute to accelerated atherogenesis (Solomon et al., 2008), cardiac risk 
being increased as non-alcoholic fatty liver disease becomes more severe. This also 
leads to an increased prevalence of type two diabetes mediated by insulin resistance 
and cardiovascular mortality, which represents the main cause of premature death in 
NAFLD.  
 
1.4 The metabolic syndrome  
The metabolic derangements that characterize the metabolic syndrome (MS) have 
been implicated in the development of NAFLD. Of all of the individual clinical 
components of the metabolic syndrome, obesity has the strongest association with 
NAFLD and generally speaking, the more obese the patient the higher the risk of 
having a fatty liver (Luyckx et al., 1998). Thirty percent of patients who are obese 
have fatty liver, and up to 80% of morbidly obese patients (BMI > 35) have NAFLD 
(Menshikova et al., 2006), regardless of BMI, patients with truncal/central  obesity 




The metabolic syndrome has been defined by the American Heart association as an 
individual exhibiting three or more of the characteristics listed table 1 (Grundy et al., 
2005). 
 
Table 1.1 Criteria for metabolic syndrome. 
Risk factor  Defining level  
Abdominal obesity (waist 
measurement) 
Men: Greater than 40 in. (102 cm) 
Asian men: Greater than 36 in. (90 cm) 
Women: Greater than 35 in. (88 cm) 
Asian women: Greater than 32 in. (81 cm) 
Triglycerides  1.7 mmol/l or higher, or taking medicine for high 
triglycerides 
High-density lipoprotein (HDL) 
cholesterol 
Men: Less than 1.03mmol/l 
Women: Less than 1.3 mmol/l 
Or taking medicine for low HDL cholesterol 
Blood pressure 130/85 mm Hg or higher, or taking medicine for 
high blood pressure 
Fasting blood sugar 5.6 mmol/l or higher, or taking medicine for high 
blood sugar  
 
It has been suggested that patients meeting any of three points highlighted in the 
above diagnostic criteria have increased risk of developing heart disease and 
diabetes. According to (Giovannucci, 2007) the metabolic syndrome also increases 
the risk of stroke, NAFLD and increased risk of liver and colon cancers. Risk factors 
associated with metabolic syndrome include a family history, poor diet and limited 
exercise; it is thought to be caused by adipose tissue dysfunction and insulin 
resistance. 
 
Although the metabolic syndrome has been linked with NAFLD, the origin and 
nature of the metabolic stressors that are involved in the progress from simple 
steatosis to NASH have as yet to be identified. Epidemiological research studies that 
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have focused on this link between the metabolic syndrome and NAFLD have only 
led to limited information as to potential interventional targets for treatments 
including nutritional and pharmacological interventions. A recent study has found 
supporting evidence that NAFLD is not invariably associated with the presence of 
the metabolic syndrome and that there may be mechanisms other than insulin 
resistance contributing to the chronic inflammation that is known to underpin liver 
fat accumulation. It has been postulated that in the absence of the metabolic 
syndrome increased haemoglobin may be a risk factor in the development of NAFLD 
(Yilmaz, 2012). 
 
1.5 Insulin Resistance 
Insulin resistance is also thought to be linked to the pathogenesis of NAFLD. Insulin 
resistance can be identified in different sites of the body. The liver where it causes an 
over production of glucose in the presence of fasting hyperinsulinaemia, the muscle 
causing a decrease of glucose uptake and utilisation and also the adipose tissue where 
the release of fatty acids is not adequately suppressed by insulin which are released 
into the blood stream (Gustafson et al., 2007). 
 
Any carbohydrate ingestion prompts a release of insulin by the pancreas in order to 
maximize storage and utilization of the glucose that will shortly be entering the 
circulation. Insulin is a hormone that is known to act through a transmembrane 
receptor on the surface of most cells. However when insulin is present in the 
circulation in elevated concentrations or for long periods of time due to dietary 
excess, these insulin receptors are down regulated, this produces the condition of 
insulin resistance within the body (Malavolti et al., 2012). It is known that a higher 
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concentration of insulin is therefore required to affect insulin signalling in the cells 
due to this insulin resistance. In the short term, insulin resistance is known to be 
reversible, in that if the blood insulin is lowered for several hours or days eventually 
the usual number of insulin receptors will return to the cell surface. However, when 
insulin has been kept chronically high for years, the resilience of the system to 
recover goes away (Gaggini et al., 2013). 
 
Eventually insulin resistance therefore becomes a constant feature in the individual, 
the liver resists turning off gluconeogenesis, muscles also resist taking up glucose. In 
most people, fat cells remain insulin responsive, but eventually they too become 
resistant and release free fatty acids from fat deposits into the circulatory system. It is 
not certain that chronic high insulin alone produces insulin resistance, for instance 
genetic susceptibility and inflammatory processes may play a role. However, once 
the symptoms of insulin resistance are observed clinically, taking steps to reduce 
chronic high insulin will permit at least a partial recovery of insulin sensitivity 
(Campbell, 2000). Not coincidentally, these actions will also cause the loss of fat 
while sparing the loss of lean muscle mass. 
 
As prevalence of disease continues to increase in conjunction with sedentary 
lifestyles and nutrient-poor calorie rich diets, and given the recognised link of insulin 
resistance with NAFLD, diet and improving insulin sensitivity by increased physical 




Figure 1.1 Insulin resistance and hepatic triglyceride accumulation, figure adapted 
from Smith & Adams (2011). 
 
According to Smith & Adams (Smith & Adams, 2011) insulin resistance promotes 
hepatic triglyceride accumulation by increasing peripheral body fat breakdown and 
free fatty acid influx as well as increasing levels of liver lipogenic transcription 
factors sterol regulatory element-binding protein 1c (SREBP1c) and carbohydrate 
response element protein (ChREBP). These are two key factors or regulators of 
glucose metabolism and lipid synthesis in the liver. An increase in hepatic free fatty 
acids (FFA) exacerbate hepatic insulin resistance via activation of a number of 
signalling pathways which have been shown to play an important role in disease 
processes. This causes a positive feedback loop, which results in a cycle of increased 
hepatic triglyceride content and hepatic insulin resistance. In a number of patients, an 
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adipose tissue inflammatory response results in the release of multiple 
proinflammatory and profibrotic cytokines. Such as tumour necrosis factor (TNF), 
interleukin 6 (IL-6) which together with liver steatosis induce oxidative stress and 
activate fibrogenic hepatic stellate cells to cause NASH, liver fibrosis and cirrhosis. 
(Smith & Adams, 2011). 
 
 
Figure 1.2 Schematic of whole–body energy distribution; adapted from original 
figure (Rabol et al., 2011).  
 
The dysfunction of adipose tissue also plays a role in the pathogenesis of obesity 
related Insulin resistance. Both adipose cell enlargement and infiltration of 
macrophages into adipose tissue result in the release of proinflammatory cytokines 
and promotes insulin resistance. (Gustafson et al., 2007). Insulin resistance appears 
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to be the primary mediator of metabolic syndrome (Gustafson et al., 2007). Insulin 
promotes glucose uptake in muscle, fat, and liver cells and can influence lipolysis 
and the production of glucose by hepatocytes. Additional contributors to insulin 
resistance include abnormalities in insulin secretion and insulin receptor signalling, 
impaired glucose disposal, and proinflammatory cytokines (Gustafson et al., 2007). 
These abnormalities, in turn, may result from obesity with related increases in free 
fatty acid levels and changes in insulin distribution (insulin accumulates in fat) 
(Despres et al., 2008). The condition also has an increased prevalence of T2DM and 
cardiovascular disease (CVD); this is thought to be mediated by the insulin 
resistance.  
 
1.6 Relevance of mitochondrial dysfunction in obesity and insulin resistance 
Research on mitochondrial dysfunction assisted in the investigation of muscle 
physiology and energy metabolism and has applications in monitoring degenerative 
diseases and testing aerobic capacities. Mitochondrial function, oxidative 
phosphorylation and glycosis account for the most important sources of cellular 
energy. In addition to producing cellular energy mitochondria are involved in cell 
signalling, a system that governs cellular activities. They are also involved in cell 
development where cells develop into more specialised cells, also cellular growth 
and division of cells and cell death. Mitochondria are known to be involved in a 
number of diseases, any dysfunction may also play a role in the ageing process 
(Broskey et al., 2013a). 
The Mitochondria account for adenosine triphosphate (ATP) production through 
oxidative phosphorylation, which as a consequence the performance of Mitochondria 
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is crucial for organ function, any dysfunction of the mitochondria can therefore play 
a role in a number of degenerative diseases including T2DM (Larsen et al., 2012). 
 
Impaired oxidative phosphorylation by skeletal muscle mitochondria have been 
postulated to contribute to age-associated insulin resistance and fat accumulation 
within skeletal muscle (Short et al., 2005a). This impaired mitochondrial functional 
capacity in aging has been attributed to a reduced mitochondrial content, as reflected 
by lower mtDNA content (Petersen et al., 2003). This study was undertaken to assess 
the role of skeletal muscle mitochondrial dysfunction and its aetiology in subjects 
with NAFLD versus age and BMI matched controls. As muscle activity increases 
demand for energy within the myofibrils increases, to provide energy for the muscle 
contraction the high energy molecule ATP is split into adenosine diphosphate (ADP) 
and inorganic phosphate as well as (H+) ions (Aliev & Saks, 1993).  
 
The aging process in humans begins around the age of 40 when muscle mass and 
strength gradually begin to decline at a rate of just under 1% per year. The process is 
caused by a decreased capacity for oxidative phosphorylation in the muscles   
(Menshikova et al., 2006). Given the strong evidence linking mitochondria 
dysfunction with aging, insulin resistance and T2DM, it is important to more 
precisely define specific loci of these defects, and perhaps more importantly, to 
determine whether clinical interventions including exercise and diet may help correct 






1.7 Indirect non invasive assessment of mitochondrial function 
Using the rate constant of Phosphocreatine (PCr) recovery as a measure of 
mitochondrial function in skeletal muscle, PCr recovery from sub maximal exercise 
has become a reliable and accepted measure of muscle oxidative capacity (Kemp GJ, 
1993). As the PCr content decreases transiently during exercise followed by a rapid 
recovery post exercise in the post state this PCr resynthesis is driven almost purely 
oxidatively. This resynthesis rate reflects in vivo mitochondrial function. This has 
been shown to be delayed in various known mitochondrial disorders. The time 
constants of PCr recovery allow evaluation of mitochondrial oxygen turnover within 
the muscle. 
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P Magnetic Resonance Spectroscopy (MRS) is thereby a unique 
method for measuring the achievements of the so-called power stations of the cell. 
Via this approach, the recovery of PCr from exercise in skeletal muscle is a reliable 
measure of capacity (Kemp GJ, 1993). In muscle physiology, mitochondrial function 
therefore as determined by the time constant of PCr recovery after a set work load, is 
of particular interest as this can be measured.  
 
1.8 Physical inactivity in NAFLD 
There are factors that have been documented to help improve metabolic flexibility. 
The first of these is mild-to-moderate exercise. In 2007, Solomon et al., described a 
12-week program of moderate aerobic exercise in older obese people that improved 
(decreased) their respiratory quotient (Solomon et al., 2008). Endurance athletes can 
be seen to show faster regeneration of PCr compared to sprint-trained athletes. 
Endurance exercise leads to mitochondrial biogenesis and hence to an increased 
mitochondrial content in the muscle (Pesta et al., 2011). Effective interventions for 
prevention and treatment of this disease are needed. Increased exercise duration and 
27 
 
intensity has been evaluated as an important therapeutic intervention (Toledo et al., 
2008). In a recent study by Broskey, which looked at exercise intervention over a 4 
month period it was found that an aerobic exercise program within older age groups 
can reduce the loss in mitochondrial content within skeletal muscle. This may 
prevent some comorbidities that can be associated with ageing muscle due to an 
improvement in mitochondrial content (Broskey et al., 2013a; Broskey et al., 2013b) 
 
Obesity is generally associated with a number of serious complications resulting in 
significant increases in life threatening diseases resulting in increased morbidity and 
mortality, relative to lean individuals. Of these complications insulin resistance, T2D 
and NAFLD are among the most prevalent. Increasing evidence suggests that regular 
physical activity reduces liver fat, independently of weight loss. Additionally, it may 
protect NAFLD patients against the development of diabetes and CVD, which are the 
leading risk factors within this group (Musso et al., 2010). These findings advocate 
the integration of physical activity as a non-pharmacological treatment of NAFLD 
however, the question arises which form of exercise would be the most time efficient 
and effective in reducing liver fat. A number of studies have compared aerobic 
training with resistance training. One existing study has demonstrated that aerobic 
training is significantly more effective at improving abdominal fat levels (McLarnon, 
2011; Bae et al., 2012), it is also apparent that weight loss and lifestyle modification 
should also be the primary target for treating NAFLD. A bi-product of exercise is a 
reduction in weight. As a normal BMI is generally not associated with NAFLD, 
weight loss even of a modest amount of 5-10% of body weight has been shown to 




In treatment of NAFLD modification of risk factors such as obesity, hyperlipidemia 
and an improvement in diabetic control are generally recommended, but weight loss 
appears to be the only available therapy that has some evidence of benefit in the 
treatment of NAFLD (Chiang et al., 2011). Lack of exercise also increases free fatty 
acids passing to the liver along with increased de novo lipogenesis, this being the 
enzymatic pathway for converting dietary carbohydrate (CHO) into fat. Another 
important source of hepatic tri-glyceride is dietary or exogenous lipids, a high fat diet 
has been shown to increase liver fat. 
 
In the period following a meal, dietary lipids are transported from the digestive tract 
into the blood stream in the form of various chylomicrons to be stored in the adipose, 
cardiac and skeletal muscle tissues. Within these tissues the triglyceride components 
are broken down and the released free fatty acids are then absorbed. When a large 
proportion have been broken down or hydrolyzed chlomicron remnants are formed 
and are then taken up by the liver, thereby transferring dietary fat to the liver.  
Following this they are processed to form very low density lipoproteins (VLDL). It 
has been shown that in overweight non-diabetics that a diet high in fat content is able 
to increase liver fat content by 35% in just a ten day period (Luyckx et al., 1998). In 
subjects with NAFLD, fat supplied by the diet is said to account for approximately 
15% of intrahepatic lipid accumulation (Paschos & Paletas, 2009). The liver is the 
major organ in the body for lipid distribution; however its ability to store fat is 
limited and any excess of is oxidised or released as VLDL. When increased this 
intrahepatic fat content leads to an increase of oxidative mechanisms in NAFLD 
patients, however non-esterfied fatty acids (NEFA) are oxidized less efficiently 
because of mitochondrial uncoupling, whereby the processing is uncoupled from the 
generation of ATP, which results in a reduction in ATP (Day & James, 1998b). In 
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subjects with NAFLD there are increased rates within the liver of VLDL triglyceride 
secretion and this circulatory source is the cause of the serum increase that is 
commonly observed in patients. Therefore it can be postulated that the progression 
from steatosis to steatohepatitis maybe due to the interaction of a number of 
mechanisms, with a genetic susceptibility in some individuals to metabolic and liver 
damage (Day & James, 1998a). 
 
Previous studies have reported beneficial effects of following diet, combined with an 
increase in physical activity on the progression of NAFLD. Based on available data, 
NAFLD patients should optimally achieve a 5-10% weight reduction, however a 
more modest weight loss would still bring a number of health benefits (Bae et al., 
2012). However weight gain of 10% by overfeeding of fast food and sedentary 
lifestyle in a study involving 18 healthy young subjects has been demonstrated to 
increase liver fat by 2.5 fold over a 4 week period (Kechagias et al., 2008).  In other 
studies, subjects with NAFLD have been shown to have dietary habits that lead them 
to consume more fat, in particular saturated fat than subjects without NAFLD. The 
intake of polyunsaturated fat consumed has also been shown to be generally lower in 
subjects that have been diagnosed with NAFLD than in those without. Within this 
group they also tend to consume foods with higher glycemic index and drink high 
calorie drinks when compared with individuals with a normal liver fat of <5% 
(Chiang et al., 2011).  
 
In small randomised studies in children weight management when used as a 
treatment have shown improvements in liver histology and aminotransferase activity 
after weight loss (Dixon et al., 2004). An emphasis on physical activity in the 
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treatment of NAFLD may be of use in improving insulin sensitivity, as insulin 
sensitivity appears to be an important link in the pathway for the development of the 
disease. These changes may be by an underlying mechanism by which improvement 
in insulin resistance may be brought about by positive changes in fatty acid 
metabolism within the muscle (Rector et al., 2010). 
 
1.9 Reversibility of mitochondrial dysfunction 
There is much evidence to support the hypothesis that mitochondrial function in 
skeletal muscle may be implicated in the development of insulin resistance and 
obesity (Kemp, 2006). A challenging issue, methodologically, is how to distinguish 
between intramyocellular and extramyocellular lipid content. This can be facilitated 
by 
1
H spectra analysis as 
1
H peaks correspond to lipids which are methylene and also 
methyl protons of the TG acyt chains within the muscle. These two peaks are 
separated by a shift in frequency from each other by 0.2 parts per million (Ppm) and 
can be seen to represent two differential compartments of an extramyocellular pool 
and intramyocellular TG (Kemp GJ, 1993). Also by using this method to non-
invasively measure hepatic liver triglyceride (TG) within our study has clear 
advantages over invasive liver biopsies. This technique was used to assess 
intramyocellular and intrahepatocellular lipids in the healthy control group versus the 
group with known NAFLD.  
 
1.10 Decreased Mitochondrial Function 
Abdominal obesity and insulin resistance have both been hypothesized to be the 
primary factors underlying the metabolic syndrome. The exact mechanisms linking 
these and other risk factors associated with the metabolic syndrome are not fully 
31 
 
understood. However ingested carbohydrates are either oxidized or stored as 
glycogen in liver and muscles, and to a lesser extent converted to fat in the liver. This 
storage represents non-oxidative glucose disposal it is suggested that impaired 
mitochondrial function has a potential link with raised intramyocellular lipids 
coupled with impaired glucose metabolism and insulin signalling (Sebastian et al., 
2012). 
 
The mitochondrion is the major site of fuel oxidation therefore it can be suggested 
that any decline in mitochondrial function may predispose to muscle fat 
accumulation. NAFLD, with its associated accumulation of fat within the liver can 
also possibly be explained by any primary defect in mitochondrial dysfunction within 
skeletal muscle (Goncalves et al., 2013). 
 
1.11 Methods to measure mitochondrial function 
When muscles are used to perform physical activity they must metabolize available 
fuel to generate energy for contraction, the harder a muscle must work, the more fuel 
is required. The relation between how hard muscles must work and their need for 
fuel is an area of interest in this study. In the past, intramuscular energy metabolism 
has been measured directly by muscle biopsies taken before and after exercise. 
 
1.12 Direct muscle biopsy 
This can be facilitated by needle biopsy in order to obtain a small quantity of muscle 
tissue; however it may not be possible to obtain an adequate sample size particularly 
if the muscle is atrophic or fatty. This is also an invasive procedure with the risk of 
infection and pain for the study patient or healthy control. Open biopsy is a more 
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reliable method in obtaining a sample large enough to do more investigations, 
however this requires the use of an operating theatre or clean room, causes some 
degree of post procedural pain and leaves a scar of approximately 5cm. 
 
1.13 Magnetic Resonance  
Principles of Magnetic Resonance Imaging 
Magnetic resonance imaging (MRI) is a non invasive imaging technique which 
produces multi slice, multi-directional images. It has no known harmful effects and is 
used for diagnostic and research studies at regular intervals without problems 
associated with regular exposure as is the case with ionising radiation. The main 
components of the magnet are the main magnet, gradient coils, radio frequency (RF) 
transmitter, receiver coils and a computer. 
 
1.14 The main magnet  
This was used to produce a strong, uniform external magnetic field i.e.  
“Bo” that is powerful enough to induce measurable tissue magnetisation. The field of 
strength being measured in Tesla (T), a 1.5T scanner was used for gaining body 
composition and a 3T scanner was used to assess mitochondrial function and PCr 
recovery. 
 
1.15 Gradient Coils  
These are electromagnetic coils with magnetic field strengths that are only a fraction 
of that of the main magnet. These gradient coils produce spatial variation in the Bo 
field (rotating frame of reference) in a calculated manner with respect to their slope 
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direction and timing. They are switched on and off very rapidly during image 
acquisition and are used to provide spatial localisation (While & Forbes, 2004). 
 
1.16 Radio frequency (RF) coils 
Radiofrequency coils transmit an RF pulse into the subject to excite sensitive nuclei 
and also receive back signals from the patient. These coils can be both transmitters as 
well as receivers; in this case they are called transceivers. Energy was transmitted in 
bursts of radiofrequency pulses this caused phase coherence and changed or flipped 
protons from low to high energy states. From this a signal was detected by the 
receiver coil. A body coil was used as this is a volume coil which covers a large area 
giving a signal to noise ratio (SNR) that is uniform over the whole imaging volume 
(Redpath & Wiggins, 2000). The computer manipulated and stored this data to 
produce images. 
 
1.17 Basic MR Physics 
All matter is composed of atoms, which consist of a central nucleus with electrons 
orbiting this nucleus at distinct energy levels. The atomic nuclei consist of protons 
and neutrons which have a positive and neutral charge, a nucleus is said to be 
observable by MR or “MR active” when it has an odd number of protons or neutrons. 
These unbalanced nuclei possess an angular momentum and as a consequence this 
makes them behave like a spinning top or gyroscope. According to the laws of 
electromagnetic induction a moving electronic charge induces a magnetic moment 
pointing along the axis of rotation of the nucleus, thus the nuclei become tiny bar 
magnets having two poles of equal and opposite polarity (Pooley, 2004). The most 
abundant unbalanced nucleus within the body is the Hydrogen nucleus which 
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consists of a single proton, it also possesses the strongest magnetic moment of any 
element, and as a consequence it is the most widely used nucleus in MR procedures 
(Pagel-Langenickel et al., 2010).  
 
1.18 Nuclei and their alignment 
The measure of the Earth's magnetic field is estimated at about 5.0 × 10
-5
 tesla 
[T = kg/Cs = 1 N/Am], standardized result 50 Ut, the hydrogen nuclei are randomly 
orientated in biological tissues and possesses a minimal magnetisation (Pooley, 
2004). Hydrogen nuclei when subjected to an external magnetic field as when a 
patient is placed in a 1.5T scanner. These nuclei align themselves either parallel or 
anti parallel in the lower or higher energy states to Bo respectively, as demonstrated 
in 1.2 the nuclei spin around an axis. 
 
Figure 1.3 Spinning nuclei, behave like spinning tops around bo. 
 
The energy states are almost equally populated as there is such a small energy 
differential between the two. The population ratio is according to Keller 100,000 to 
Magnetic Resonance Nuclei, protons and spins
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100,006 (Keller, 1988). The nuclei are in fact tilted at an angle and behave like 
spinning tops, precessing around Bo as demonstrated in figure 1.3. 
 
Figure 1.4 Nuclei precessing around Bo as demonstrated above. 
 
As can be seen in figure 1.4 there is a random alignment of nuclei when in the 
absence of an external magnetic field. 
 
.  
Figure 1.5 Random alignment of nuclei when in the absence of an external magnetic 
field. 
Magnetic Resonance Precession 
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Figure 1.6 Magnetic resonance nuclei in magnetic field align parallel and anti-
parallel 
 
However following the application of an external magnetic field (Bo), as in a 1.5T 
scanner nuclei align parallel and anti-parallel, as can be seen in figure 1.5. Because 
of the influence of Bo this causes the hydrogen nucleus to wobble or precess, which 
can be likened to a spinning top as it comes to rest, the axis of the nuclei forms a path 
around Bo which is known as the precessional path. This precessional frequency is 
termed the Larmor frequency as expressed in the following equation (Keller, 1988) 
which shows the relationship between the previously mentioned factors. 
 
Larmor frequency = gyromagnetic ratio x external field 
(mHz)                  (mHz/Tesla)              (Tesla) 
 
This equation indicates that if the strength of the magnetic field changes this affects 
the speed at which hydrogen precesses dependant on the strength of Bo and is termed 
the precessional frequency. The precessional frequency of hydrogen in a 1.5T 
magnetic field is =63.86MHz. The precessional paths of hydrogen nuclei on an 
individual basis are random or out of phase, however they need to be in phase to 
Magnetic resonance nuclei in a magnetic field  









resonate. Resonance occurs when an object is exposed to an oscillating perturbation 
with a frequency which is close to its own inherent frequency of oscillation. This 
frequency in a 1.5T magnetic field can be found in the RF band of energy in the 
electromagnetic spectrum. Application of a radiofrequency pulse produces 
radiofrequency energy which following the law of electromagnetism, charged 
particles in motion will generate a magnetic field which is known as B1. Which when 
applied as a pulse during MR sequences this causes B1 to flip, the degree of which 
this net magnetization is deflected is termed the flip angle (Keller, 1988). 
  
 
Figure 1.7 As can be seen in figure 1.6 the nuclei precess in phase in the B1   plane 
this creates a changing magnetic field, the flip angle is proportional to the duration 
and amplitude of the RF pulse (Keller, 1988). This information is collected by the 
coil being used and is then encoded through mathematical calculations, the resultant 
data is stored; it is this data which formulates the image. 
 
During Resonance
The hydrogen atoms begin to precess “in phase”










1.19 Magnetic Resonance Spectroscopy (MRS) 
Magnetic resonance Spectroscopy can be used in order to assess microscopic 
chemical and physical information about molecules. It can identify various 
metabolites and biochemical components within body tissues non-invasively 
(Bachert & Schroder, 2003). MRI and MRS utilise atoms that have positively 
charged nuclei and possess a property called spin where they precess around their 
axis. A spinning charge generates a magnetic field that results in a magnetic moment 
proportional to the spin. Within their natural environment the nuclei exist randomly, 
when subjected to an external magnetic field as in an MR scanner, the nuclei act as 
tiny dipole magnets and will align either parallel or anti parallel to the external 
magnetic field. The speed at which the nuclei precess is dependent upon their 
inherent properties, the media in which they exist and the strength of the external 
magnetic field it is subjected to and is termed the precessional frequency. This 
difference causes a chemical shift i.e. small frequency differences between signals 
from protons therefore the intensity of the metabolic signal is directly related to its 
concentration (Bachert & Schroder, 2003). 
 
The principles of MRS are broadly similar to Magnetic Resonance Imaging (MRI) 
however a number of differences do exist. The images obtained by MR use the whole 
proton signal from tissues dominated by fat and water protons. However other 
metabolites do not contribute to this imaging due to the small concentration of 
protons. MRS is designed to detect these small metabolites which resonate between 
the frequencies of fat and water. In order to do this the large water proton signal 
needs to be suppressed, smaller tissue metabolites are then detected from chemical 
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shifts, whereas in MRI this causes artefacts. This chemical shift provides information 
about the structure of the molecule. 
 
MRS measures the chemical content of MR-visible nuclei including the 
metabolically relevant elements, for the purpose of this study Phosphorous was used 
(
31
P). This is advantageous when assessing metabolism as the chemical properties of 
the nuclei of interest are expressed at certain frequencies within the MR spectrum, 
giving rise to peaks correspondent to these Phosphorus metabolites (Jeneson et al., 
2008). Repeated measurements of these metabolites and associated metabolic 
changes make MRS ideally suited in monitoring responses to the exercise 
intervention within this study, as it allows a real time dynamic monitoring of in vivo 
muscle metabolism and ATP turnover. Rate constant of PCR recovery can be 
monitored following the two periods of exercise from analysis of the 128 spectra 
taken during the MRS exercise protocol (Kemp & Radda, 1994). Within this study a 
31
P radiofrequency (RF) coil was used as this has the sensitivity to assess the nuclei 
of interest, which within this study are gamma, alpha, delta ATP and Phospocreatine.  
 
The magnetic fields need to be at least 1.5T to facilitate satisfactory MRS signals, a 
3T scanner was used within this study as Phosphorous (
31
P) has a lower Larmor 
frequency than hydrogen and a higher field strength is required in order to achieve 
good spectral resolution. Phosphorus is a major component in adenosine triphosphate 
(ATP) this being consumed and renewed in the conversion of sugars to energy and 
can therefore be used to study muscle metabolism at the mitochondria. Although 
MRS cannot completely replace the direct biochemical measurements obtained from 
muscle biopsy samples, it has distinct advantages that are not available with biopsies. 
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It provides a non-invasive direct measurement of muscle energy metabolite 
concentrations (glycogen, creatine phosphate, glucose 6-phosphate, inorganic 
phosphate, and lactate) with better time resolution, repeatability, and better precision 
(Kemp & Radda, 1994). 
 
Exercise causes a decrease in the in the PCr signal and an increase in the Pi signal, 
changes in muscle PH can be detected by this shift in the Pi peak frequency. The 
spectral peaks can be converted into meaningful metabolic measures from the 
physiological concentrations.  Using the rate constant of PCr recovery as a measure 
of mitochondrial function in skeletal muscle, phosphocreatine (PCr) recovery from 
sub maximal exercise has become a reliable and accepted measure of muscle 
oxidative capacity (Kemp & Radda, 1994). 
 
 
Figure 1.8 Rate constant of PCr recovery as a measure of mitochondrial function in 
skeletal muscle. 
 
Figure 1.8A saturated transfer spectra of PCr and γATP in blue before depletion and 
highlighted in black post depletion, figure 1.8B shows Mono-Expodential fit of PCr 
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recovery following exercise. This has a place in investigating muscle physiology and 
energy metabolism and has applications in monitoring degenerative diseases and 
testing aerobic capacities. Mitochondrial function and Oxidative phosphorylation and 
glycosis account for the most important sources of cellular energy. The Mitochondria 
account for ATP production through oxidative phosphorylation, which as a 
consequence performance of Mitochondria is crucial for organ function, any 
dysfunction of the mitochondria can therefore play a role in a number of 
degenerative diseases including type II diabetes (Petersen et al., 2003).  
 
As muscle activity increases demand for energy within the myofibrils increases, to 
provide energy for the muscle contraction the high energy molecule adenosine 
triphosphate (ATP) is split into adenosine diphosphate (ADP) and inorganic 
phosphate as well as (H+) ions. In studying oxidative metabolism this is dependent 
on the relationship between oxidative turnover of ATP and the concentrations of 
ADP, phosphcreatine (PCr) and inorganic phosphate. Initially as muscle is exercised 
ATP use temporarily runs ahead of ATP synthesis, due to the workings of creatinine 
kinase equilibrium which ensures that this shortfall initially is made up but this is at 
the expense of a decrease in the concentration of PCr , this is associated with an 
increase in concentration of ADP, this plays a role in the feedback stimulation of 
oxidative ATP synthesis (Kemp, 2006).  
 
In studying oxidative metabolism this can be approached by measurements of steady 
state and also recovery kinetics. As exercise increases there is a fall in PCr and a rise 
in Pi such that their sum remains constant ATP being buffered at a constant value 
(Kemp & Radda, 1994). At higher levels of exercise the pH falls moving the Pi peak 
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to the right as the chemical shift difference from PCr decreases. The time constants 
of PCr recovery allow evaluation of mitochondrial oxygen turnover within the 
muscle. 
31
P MRS spectroscopy is thereby a unique method for measuring the 
achievements of the so-called power stations of the cell. Via this approach, the 
recovery of PCr from exercise in skeletal muscle is measurable (Kemp, 2006).  For 
this reason in muscle physiology, mitochondrial function determined by the time 
constant of PCr recovery after a tiring load, is of particular interest as it is 
measureable. 
 
1.20 Study Aims 
NAFLD, which is characterized by lipid deposition effecting greater than 5% of 
hepatocytes, has an association with the metabolic syndrome and insulin resistance. 
It has been suggested that an impairment within the skeletal muscle in mitochondrial 
function may be a contributory factor to ectopic fat accumulation within the liver 
(Johannsen et al., 2012). Therefore, the aim of this study is to use rate constant PCr 
recovery data to look at mitochondrial function in age and BMI matched controls 
versus subjects with Non Alcoholic Fatty Liver Disease.  
 
1.21 Objectives 
The objectives of this study is to recruit 15 controls and 15 subjects with known 
NAFLD age, BMI, and fitness matched, to investigate any differences in 
mitochondrial function. As evidence suggests that mitochondrial function within 
skeletal muscle may have an involvement in the development of obesity and insulin 
resistance (Menshikova et al., 2006). We will determine body composition allowing 
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quantification of total fat, total sub-cutaneous, abdominal sub-cutaneous adipose 
tissue, total visceral, and abdominal visceral fat by carrying out whole body MRI. 
Liver fat will also be determined and quantified, this will be determined by Magnetic 
Resonance Spectroscopy, and results will be expressed as a percentage ratio of the 
CH2 lipid peak relative to the water peak from the spectra obtained. 
 
We hypothesise that this investigation may enable us to determine if mitochondrial 
dysfunction within skeletal muscle has a link to ectopic fat accumulation within the 
liver, and the associated metabolic syndrome by altering energy storage. We will also 
obtain within this study other measurements including aerobic fitness, via VO2peak 
testing, anthropometrics and various blood tests on all individuals, to look at any 




































2.1 Inclusion & Exclusion criteria 
Inclusion criteria 
All subjects were over 18 years of age with no history of regular structured exercise 
or highly physical employment. Male participants consumed <21 units of alcohol per 
week and females <14 units, recorded by a screening questionnaire. A clinical 
diagnosis of NAFLD was based upon the following criteria;  
(i) Exclusion of other causes of liver disease such as Hepatitis B and C serology, a 
negative auto-immune profile and normal caeruloplasmin concentrations;  
(ii) Ultrasound appearances suggestive of fatty liver with no evidence of cirrhosis, in 




Participants were excluded if they reported alcohol consumption that exceeded the 
recommended guidelines of >21 units a week for men and >14 units for females. 
Consumption of certain prescription medications known to cause secondary 
steatohepatitis, such as amioderone, tamoxifen or methotrexate were grounds for 
exclusion. Persons with a contraindication to attaining the various positions within 
the scanner due to shoulder mobility issues, as the prone position is required for two 
of the scans. Patients with type 2 diabetes were excluded as we are examining the 
involvement of insulin resistance when it is at a reversible stage and before beta cell 
failure has occurred. Individuals with contra indications for MRI scanning, for 
example those with metal implants for safety reasons and those who suffer from 
claustrophobia were also excluded. 
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In total 17 subjects with NAFLD (mean±SD) age 47±11yrs; BMI 31.6 ± 3.4 kg/m
2
 
and 18 controls matched for age (47±17 yrs) and BMI (30.5±5.2 kg/m
2
). None of the 
controls were taking any prescribed medication and all had liver transaminases 
within normal range. Allocation of subjects to either the NAFLD or control group 
was only confirmed following confirmation that liver triglyceride content was either 
<5.5% for the controls or ≥5.5% for the NAFLD group. Analysis of data following 
MRS of the liver was assessed and quantified; some subjects originally joining the 
study as a control were allocated to the NAFLD group and one subject thought to 
have NAFLD was allocated to the control group. 
 
2.2 Subject recruitment 
Patients were recruited via the Liver clinics at Royal Liverpool University Hospital 
and University Aintree Hospital. Patients attending the Hepatology clinics who had 
been diagnosed with NAFLD and who on initial assessment met the inclusion criteria 
were invited to participate in the study. They were approached by their physicians or 
affiliated research nurses and the research study was verbally discussed. Follow up 
and initiation onto the study occured after participants had read the patient 
information sheet. The content and requirements of the study were discussed by me, 
as the facilitating research nurse, and any questions answered prior to obtaining 
signed informed consent, a copy of which was given to each participant for their 
records. Age and BMI matched controls were recruited following their response to 





All participants attended the laboratory on two different occasions. Measurements 
were taken following an overnight fast, they were also required to abstain from 
caffeine for a 12 hour period and not undertake strenuous exercise or drink alcohol 
for a 24 hour period prior to attending for their scan and blood samples.  
 
2.3 Ethical considerations 
The study conformed to the Declaration of Helsinki and was approved by the local 
research ethics committee. All participants were informed of the methods verbally 
and in writing before providing informed written consent prior to any tests being 
performed. 
 
2.4 Safety of magnetic resonance imaging (MRI)  
All individuals were initially screened either in person or over the phone prior to 
their attendance at the MRI centre; a number of individuals were excluded at this 
stage. On arrival, the subject was required to fill in a safety questionnaire. Whilst 
MRI is a relatively safe imaging technique, as it does not involve ionizing radiation, 
there are a number of hazards to both patients and staff working in the department. 
The MRI system and the surrounding environment are potentially hazardous. 
Primarily if a ferromagnetic object, for example one containing iron or steel, is close 
to the magnet it will experience a force known as ferromagnetic attraction. If this is 
close to the magnet the object can be turned into a projectile and therefore items such 
as scissors could therefore be fatal to the occupant of the scanner or staff in 
attendance. The larger the object the greater the force, even in the absence of field 
changes any ferromagnetic object will twist with force that is much greater than its 
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mass in an attempt to align along its axis with static field lines of force; this twisting 
is known as torque (Vonsmekal et al., 1995). 
 
This ability to twist objects and the magnets ability to turn objects into projectiles is a 
major risk facture; this ability extends beyond the immediate area around the scanner 
and is referred to as the fringe field, in order to ensure safety a controlled area is 
clearly defined. As well as completing a safety questionnaire, participants were also 
screened in person to ensure that they were safe to enter the scanning area by a 
member of staff who has the authority to sign the form passing the person as ‘safe to 
scan’. Participants with any history of internal metal, pacemakers, or ferromagnetic 
metallic implants, intraocular foreign bodies or cerebral aneurysm clips were denied 
access to the scanning area. A number of volunteers were excluded from the study 
for safety reasons due to the presence of ferromagnetic objects. Some subjects had a 
history of eye injury due to industrial accidents and although they gave a history of 
the foreign object having been removed they were excluded as small fragments could 
remain. The scanner is noisy during operation this is caused by vibrations of gradient 
coils; levels of this can exceed safety guidelines as the noise increases with heavy 
duty cycles and sharper pulse transition. For this reason, all volunteers for the study 
were issued with ear-plugs. In addition to this during magnetic resonance 




A major safety consideration was the length of exposure time that volunteers were in 
the scanner, when both body composition and mitochondrial scans were both 
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performed on the same day. The body composition scan required four separate scans 
with positional changes for each data acquisition, total scan time of approximately 
one hour in a 1.5 Telsa (T) MR scanner. This was followed by a scan were the 
volunteer performed exercises in a 3T MR scanner lasting ~45 minutes. This 
required the Specific Absorption Rate (SAR) to be calculated, as the doubling of 
field strength from 1.5 T to 3T leads to a quadrupling of SAR. RF Pulse can be 
defined as a burst of energy; this energy rotates the magnetisation away from the axis 
of the magnet to create a transverse magnetisation. A 90 degree pulse will rotate the 
magnetisation by 90 degrees. 
 
Radio frequency (RF) magnetic fields can result in energy deposition and produce 
tissue heating, SAR is a measure of tissue energy deposition, its unit of measure is 
Watt/Kg the limit for clinical examination is SAR<0.4W/Kg, in order to prevent soft 
tissue heating of >1 degree Celsius (Vonsmekal et al., 1995). Ensuring the safety of 
participants in this instance involved entering each participant’s weight into the 
computer during the scanning protocols, which gave a calculated SAR value and a 
scan time limit before the limit was reached. 
 
2.6 Biochemical measurements 
Plasma samples were analysed using the Olympus AU2700 analyser (Beckham 
Coulter, High Wycombe, UK). Fasting blood samples were taken for fasting glucose, 
also a further spun sample was used for insulin levels from which HOMA-IR as an 
index of insulin resistance was calculated, this is a method used to quantify insulin 
resistance and beta cell function using the equation (fasting glucose x fasting insulin / 
22.5). Fasting Lipid profiles were also taken including total cholesterol Triglycerides, 
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low density lipoproteins (LDL), high density lipoproteins and cholesterol: HDL ratio 
was calculated. The intra- and inter-assay coefficient of variation was ≤10%. Low-
density lipoprotein (LDL) was calculated according to the Freidwald formula. Serum 
liver enzymes were taken for aspirate aminotransferase (AST), Alanine 
aminotransferase (ALT) and Gamma-glutamyltransferase (GGT) with International 
Federation of Clinical Chemistry (IFCC) kinetic UV (without pyridoxal phosphate 
activation). A full blood count to gain platelet counts was also obtained, along with a 
further spun sample which was used to obtain free fatty acid levels. Caeruloplasmin 
levels were also taken to exclude Wilson’s disease. All laboratory assays were 
performed in the clinical laboratory at the University Hospital Aintree, Liverpool. 
 
2.7 Anthropometric Measurements 
After a full medical history was obtained and a physical examination, a single 
observer performed all the anthropometric assessments to ensure continuity of 
measurements. Height was measured in all individuals using a Seca 216 wall 
mounted device rounded to the nearest 0.5cm, as height differed from the expressed 
height in patients and controls. Waist measurements were taken at the umbilicus and 
the hip at the greater trochanter to facilitate calculation of waist hip ratios in all 
participants. This measurement was recorded during the study as waist circumference 
is typically used in clinical practice to both quantify abdominal obesity and to make 
the diagnosis of metabolic syndrome. Whereas the waist hip ratio can be used to 
assess risk of fat related diseases, subjects may be at a healthy weight based on their 
BMI but waist hip ratios above 0.8 for females and 1.0 for males are associated with 
obesity and can be linked to increased risk of health complications and diseases 
including NAFLD and heart disease (Czernichow et al., 2011). Assessment of body 
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composition was taken on all subjects using Tanita bio-impedance SC- 331S scales; 
this facilitated a print out of total body composition readings including: weight, fat 
percentage, fat mass, total body water, muscle mass, basal metabolic rate, bone mass, 
visceral fat indicator, and body mass index. Blood pressure was taken using a manual 
Reister Big Ben desk top sphygmomanometer from all subjects at the point of their 
attendance for their body composition scan.  
 
 
Figure 2 The Coronal view above left follows front to back, as though cutting 
through a corona, in medical terms anterior means the front and posterior means the 
back of the body. A transverse view, or Axial as left, is formed by a series of 
circumferential slices these transverse sections run from the top of the body 
(superior) to inferior or lower down the body. In the Coronal view in figure 2 the 
body fat can be seen as yellow/white in colour and in the axial view the fat mass is 





2.8 Maximal Oxygen Consumption Test ( VO2peak) 
All subjects were required to carry out a fitness test at the start of the study in order 
to assess their aerobic capacity. This was facilitated by using a treadmill Ergometer 
(H/P/ Cosmos, Pulsar 4.0, Nussdorf-Traunstein, Germany) within an air conditioned 
environment. The Modified Bruce treadmill protocol (Sotelo-Peryea et al., 2010) was 
used which was designed in 1963 by Robert. A. Bruce, MD, as a non invasive 
method for estimating VO2peak or maximal oxygen uptake. This was used to 
determine each of the participant’s capacity to perform sustained exercise which is 
linked to aerobic endurance capability. VO2peak refers to the maximum amount of 
oxygen that an individual can utilize during intense or maximal exercise. It is 
measured as "millilitres of oxygen used in one minute per kilogram of body weight" 
(ml/kg/min).  
 
The treadmill speed and incline was progressively increased after an initial 2-min 
warm up which was at 2.2 Km.h
-1 
on a flat gradient, thereafter step-wise increments 
in speed and grade were employed every minute. Their VO2peak was calculated from 
minute to minute ventilation, this was measured using a pneumotach and 
simultaneous breath-by-breath analysis of expired gas fractions (Oxycon Pro, Jaegar, 
Germany). All machines used were calibrated before each test to ensure validity of 





Peak oxygen consumption was calculated as the highest consecutive 15 second 
period of gas exchange data which occurred in the last minute before exhaustion, 
which usually occurred due to leg fatigue or breathlessness. A respiratory exchange 
ratio (RER) of 1.15 combined with a maximal heart rate of 90% of age predicted 
maximal heart rate, which was calculated as 220 minus the participant’s age. During 
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this V02peak their heart rate was continuously measured (Polar Electro Oy, Finland). 
Participants condition was also monitored using the BORG scale this scale allowed 
participants to point to the level of perceived difficulty they felt at periodic intervals. 
Following a 2-min warm up at 2.2 Km.h
-1 
on a flat gradient, the initial workload was 
set at 2.7 Km.h
-1 
at a 5% gradient. 
 
2.9 MRI scanning and determination of body composition 
In order to obtain data on body composition a Siemens Symphony 1.5 Tesla scanner 
(Siemens Medical Solutions, Erlangen Germany) was used to acquire imaging data. 
All scanning was carried out at the University of Liverpool Magnetic Resonance and 
Image Analysis Research Centre, a single experienced radiographer (VA) carrying 
out all scans (Gardner et al., 2011). Quantification of total fat, total sub-cutaneous, 
abdominal sub-cutaneous adipose tissue, total visceral, and abdominal visceral fat 
was facilitated, by carrying out a whole body Magnetic Resonance scan. Whole body 
axial T1-images were obtained from a set of fast spin echo scans, with a slice 
thickness of 10mm followed by a gap of 10mm with a TR of 705ms and a TE 12ms 
using the integral body coil. This was acquired in 10 slice, contiguous blocks with 
table movement between to minimise in homogeneity. The resultant data being 
analysed by Vardis (Vardis Group Inc., London UK) using SliceOMatic 
(Tomovision, Montreal, Canada).  
 
In this study whole body scanning was firstly used to produce quantification of total 
body fat for each participant, also intrahepatocellular and intramyocellular lipids 
were measured. On a number of occasions controls were found to have greater than 
5% liver fat so they were reclassified as NAFLD and included within this group for 
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the study. Their GP was informed for their information and future treatment 
prescribed as required. There were four basic steps involved in obtaining an MR 
image; firstly the research volunteer was placed in the magnet where radio frequency 
pulses were sent by a radiofrequency (RF) coil. These signals were received by the 
coil and then sent to the computer for processing in order to get an image from which 
total body fat could be assessed and computed.  
 
2.10 Liver MRS 
MRS provides biochemical information by tuning the MR system to identify signals 
from different chemical nuclei such as Hydrogen (
1
H) and Lipids (Ch
2
), which are 
indicative of intrahepatocellular water and fat content (Reeder et al., 2011). In the 
same imaging session as body composition scans quantification of intra hepatic fat 
was also gained by using Magnetic Resonance Spectroscopy (MRS) protocols, T2 
weighted true fisp images through the liver were used for optimum positioning of the 
spectroscopy voxels. This was facilitated by placement of three voxel’s within the 
liver to gain data on intrahepatocellular lipids avoiding ducts and vasculature within 
the liver structure. Voxel size was 20
3
mm with an echo time TE of 135ms, TR 
1500ms, with 64 acquisitions. An image segmentation software program was used to 
analyse the images, in which liver contours were manually drawn for each slice 
(Saeed et al., 1998). Liver volumes were calculated from this by multiplying the liver 
tissue volume of each slice by slice thickness (6mm). 
 
1
H MR spectra were acquired at 1.5T from the liver using a PRESS sequence, (TR 
1500ms/ TE 135ms) without water saturation and with 64 signal averages, transverse 
images of the liver were used to ensure accurate positioning of the voxel in the liver. 
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The AMARES algorithm included in the MRUI software package jMRUI-3.0 was 
used to analyse 
1
H MR Spectra in the time domain (Vanhamme et al., 1997; Naressi 
et al., 2001). After correcting for T1 and T2, peak areas for all resonances were 
obtained and lipid resonances were quantified with reference to water resonance 
(Thomas et al., 2005). These T1 and T2 values for IHCL were obtained by a single 
experienced Radiographer for all subjects within the study to avoid any variance of 
operation. 
 
Results are expressed as percentage ratio of the CH2 lipid peak area relative to the 
water peak area from the spectra obtained (Zhong et al., 2009).  To assess the 
reproducibility of the 
1
H MRS results, analyses were repeated in triplicate and the 
coefficient of variation measured between the three voxels. Quantification of fat 
using 
1
H MRS has been validated against gold standard biochemical measurements 
(Szczepaniak et al., 1999). As previously described Magnetic Resonance 
Spectroscopy (MRS) protocols were used to gain data on the intrahepatic fat, using 3 
different voxel positions  figure 2.1 within the liver, taking care to avoid inclusion of 
intra hepatic ducts,  vessels and any overtly fatty areas which appear as white areas 




Figure 2.1 Voxel placements for liver spectroscopy. 
 
Above can be seen an axial image of a liver with three voxel positions for liver 
spectroscopy, these can been seen as the black outlined box’s within the liver 
structure. The positioning was facilitated by using different planes to allow three 
dimensional positioning. The associated hepatic lipid and water peak that are 
obtained for analysis and quantification can be seen in figure 2.2, this allowed an 




Figure 2.2 Liver spectroscopy peaks above left showing water and lipid signals, 
coronal middle right and axial scanning views above and bottom right  
 
These coronal and axial views helps facilitate a three dimensional view of voxel 
placement as can be seen on the right in figure 2.2, the peaks on the left represent 
intrahepatecellular water spectrum whilst the lipid signal peak represent 
interhepatecellular lipids, measured in chemical shift in parts per million. 
 
2.11 Magnetic resonance spectroscopy 
This was carried out in both groups, to obtain a quantification of intrahepatocellular 





2.12 Liver spectroscopy NAFLD group                                                       
 
Figure 2.3 NAFLD group liver spectroscopy peaks, coronal middle right and axial 
scanning views above and bottom right  
                                               
As in figure 2.3, liver spectroscopy from a NAFLD subject in the study, the peaks on 
the left represent the intrahepatecellular water spectrum whilst the peak on the right 
represents interhepatecellular lipids spectrum. The level of liver fat after 





2.13 Liver spectroscopy Control group 
 
Figure 2.4 Control group, liver spectroscopy peaks, coronal middle right and axial 
scanning views above and bottom right. 
 
Figure 2.4 shows the control group the peak on the right representing the 
intrahepatocellular lipid content was visibly lower and was 1.1% in this subject. This 
was carried out by referencing the voxel position in three planes, namely axial, 
sagittal and coronal, facilitating a near three dimensional guided placement. One 
interesting finding was that there was a variance in the levels of liver fat in some 
individuals within the three areas that were assessed, whilst in others it was relatively 
the same. The average of the intrahepatocellular lipid content from all three data 
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acquisitions was therefore used. 
 
2.14 Intramyocellular lipid assessment 
Image-guided, localised proton magnetic resonance spectra of the left soleus and 
tibialis anterior muscles were generated on a Siemens Symphony 1.5T scanner 
(Siemens Medical Solutions, Erlangen Germany). For this the subject lay supine 
within the MR scanner with a circularly polarized extremity coil around their left 
calf. Spectra were collected from a voxel similar to that used for the liver 
spectroscopy with the exception of  when the musculature was too small requiring a 
smaller voxel size (15 x 15 x 20) in this case the number of acquisitions increased (to 
200) to maintain the signal to noise ratio (SNR). 
 
IMCL peaks were represented as CH2 lipid amplitude in relation to total creatine 
amplitude following correction for T1 and T2 (Gardner et al., 2011). In total four 
positional changes were required, total scan time was approximately one hour for the 
body composition scan.  As illustrated in figure 2.5 the tibialis anterior and the soleus 
muscles were used to obtain quantification of intramyocellular lipids for both 
NAFLD and control groups within the study. Anatomy and  voxel placement varied 
when detemining lipid content, the placements being made to avoid blood vessels 





Figure 2.5 Axial views of the Soleus and Tibialis Anterior muscles showing voxel 
placement and intramyocellular lipid data above right 
 
Intramyocellular fat was also assessed by using Magnetic Resonance Spectroscopy 
(MRS) by placement of two voxels within the tibialis anterior and the soleus muscle 
(Figure 2.5). In all total fat, total subcutaneous, abdominal subcutaneous, total 
visceral, abdominal visceral, liver fat %, and Intra-myocellular fat in the tibialis and 



















Skeletal muscle: intramyocellular lipid (IMCL) content
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2.15 Skeletal muscle Intramyocellular Lipid assessment 
 
Figure 2.6 MRS of the Tibialis anterior muscle spectroscopy peaks the larger peak 
on the left being intramyocellular water whilst the peak on the right is 
intramyocellular lipids, coronal and axial scanning views above right. 
                                   
The views in figure 2.6 are representative of voxel placement in the tibialis anterior 






Figure 2.7 MRS of the Soleus muscle spectroscopy peaks the larger peak on the left 
being intramyocellular water whilst the peak on the right is intramyocellular lipids, 
coronal and axial scanning views above right. 
                                                                    
The intramyocellular lipid content was 3.6% in the tibialis and 11.7% in the soleus 
muscle within this subject from the NAFLD group. 
 
2.16 Background to methods 
The focus of this study is to use rate constant PCr recovery data to look at 
mitochondrial function in normal controls versus subjects with NAFLD, taking into 
consideration other measurement modalities of aerobic fitness. VO2 peak is 
64 
 
expressed either as an absolute rate in litres of oxygen per minute (l/min) or as a 
relative rate in millilitres of oxygen per kilogram of bodyweight per minute 
(ml/kg/min). This last modality, VO2 Peak ml/kg/min has been used in testing on all 
subjects within this study. 
 
MRS provides biochemical information by tuning the MR system to identify signals 
from different chemical nuclei such as Hydrogen (
1
H) & Phosphorous (
31
P), which 
are indicative of intracellular muscle fat and high energy phosphates within the body 
respectively. The use of non-invasive 
31
P MRS in vivo protocols were used to 
measure inorganic phosphate (Pi), phosphocreatine
 
(PCr), and Adenosine 
Triphosphate (ATP) within the muscle
 
tissue to track changes in cell recovery.  
 
2.17 MRS Quadriceps Muscle  
For both the NAFLD and control groups 
31
P MRS assessments of muscle 
mitochondrial function in the quadriceps muscle were carried out using a Siemens 3T 
Trio MR scanner (Siemens AG, Erlangen, Germany) using an isometric knee 
extension exercise protocol as developed by the Magnetic Resonance and Image 
Analysis Research Centre facility at Liverpool University (Kemp GJ, 1993). Subjects 
lay supine (secured with a Velcro strap across the hips) with the right knee flexed by 
c. 30° over a rigid foam support in a custom-built rig permitting isometric knee 
extension exercise against a strap across the anterior lower shin/ankle connected to 
an aluminium bar fitted with a strain gauge. 
31
P MRS data were acquired from right 




H surface coil 
(RAPID Biomedical, Rimpar, Germany), Velcro-strapped to the anterior thigh 
(midway between anterior superior iliac spine and patella). After automated set-up 
65 
 
and manual shimming using tissue water, an 8-scan fully relaxed (TR=10s) and a 32-
scan partially saturated (TR=2s) resting spectra were collected.  The exercise 
protocol consisted of 1.1 min rest followed by 2 bouts of isometric exercise each 
followed by 5.2 min recovery periods, while spectra were collected (TR=2) every 8 s 
paced at 0.25 Hz (2 s on, 2 s off) by an audible cue, exercise force being feedback 
visual via an LED display visible at the end of the bore through a head mirror. Two 
exercise intensities were used, corresponding to 70% and 90% of maximal voluntary 
contraction established in 3 brief trials prior to MRS acquisition (in pilot experiments 
these intensities were found to give acceptable PCr depletion with minimal 
acidification in typical subjects (Kemp, 2006). All spectra were acquired with 
Nuclear Overhauser enhancement (NOE), using 1H spins were saturated by 10 
radiofrequency pulses (900 flip angles), 5 ms pulse duration, and 10 ms interpulse 
delay. Block MRS data output files from exercise-recovery acquisitions were 
converted to text using a specially-written Matlab routine (courtesy of Dr Damian 
Tyler, University of Oxford). All 
31
P MRS data were processed using the java-based 
Magnetic Resonance User Interface (jMRUI v.3.0), using the AMARES time-
domain fitting algorithm. Data were fitted assuming Lorentzian line shapes for PCr, 
Pi, PDE, PME, NADP and ATP (β-ATP a 1:2:1 triplet, α-ATP and γ-ATP both 1:1 
doublets), using prior knowledge files kindly supplied by Dr Damian Tyler, 
University of Oxford. The chemical shift of the inorganic phosphate (Pi) peak 
relative to phosphocreatine (PCr) (σ parts per million) was used to determine 
intracellular pH. PCr recovery time courses were fitted to a monoexponential 
function to determine the recovery rate constant (k min
-1
). In the absence of 
appreciable changes in pH (as here), this is accepted as a measure of effective muscle 
mitochondrial function, the latter being a system property which reflects 
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cardiovascular oxygen supply and mitochondrial oxygen usage (Johannsen et al., 
2012).  
 
The purpose of this study was to prospectively evaluate subjects using this method 
by the noninvasive assessment of muscle metabolites during exercise. Hydrogen 
(
1
H), inorganic phosphate (Pi), phosphocreatine
 
(PCr), and Adenosine Triphosphate 
(ATP) within the muscle were measured by magnetic resonance (MR) spectroscopy. 
Peaks were measured during muscle contraction allowing the kinetics of PCr rate 
constant to be assessed continuously before, during, and after a period of exercise 
and quantified post scan for statistical analyses. Using this PCr rate constant muscle 
oxidative capacity was therefore measured as it allowed mitochondrial oxygen 
turnover within the quadriceps muscle to be obtained using this unique method of 
31P Magnetic Resonance Spectroscopy. 
 
From this data differences in PCr rate constant between the NAFLD group and age 
and BMI matched controls were assessed, the two groups being well matched with 
no significant differences in age, total body weight, body mass index or percentage 
body fat mass (table 3.1).  
 
2.18 Mitochondrial function assessment protocol 
The use of non-invasive 
31
P MRS in vivo protocols were used to measure inorganic 
phosphate (Pi), phosphocreatine
 
(PCr), and Adenosine Triphosphate (ATP) within 
the muscle
 
tissue to track changes in cell recovery during the programme. 
Mitochondrial function was assessed during the study by measuring Phosphocreatine 
(PCr) recovery kinetics. 
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MRS provides biochemical information by tuning the MR system to identify signals 
from different chemical nuclei such as Hydrogen (
1
H) & Phosphorous (
31
P), which 
are indicative of intracellular muscle fat and high energy phosphates within the body 
respectively (Kemp & Radda, 1994). Changes in cell energy expenditure and 
recovery were measured during a scan in which subjects performed leg extension 
exercises for a set number of repetitions. These were at two points of intensity 25 
repetitions at 90% followed by 15 at 70%. This exercise resistance methodology to 
facilitate assessment of the leg muscle within the scanning protocols was developed 
by the Magnetic Resonance and Image Analysis Research Centre facility at 
Liverpool University. The quadriceps muscle was used for this assessment, for 
practical reasons, as not many muscles are accessible to 
31
P MRS from an anatomical 
or practical perspective, also the quadriceps is probably less vulnerable to subclinical 
microvascular disease than the calf muscle. Due to the set up of the exercise 
equipment the right leg was used in all but one subject during the study. 
 
 
Figure 2.8 LED bar graph readout showing arrows at 70% and 90% of MVC to 




Figure 2.9 Exercise rig positioning and 
31
P coil placement over the quadriceps 
muscle to enable data acquisition. 
 
Figure 2.10 final positions in the scanner for data acquisition all but the head being 
enclosed. 
  
The subject received feedback on how much force they generated from viewing an 
LED bar graph above their head via a head band mounted mirror figure 2.8. Their 
maximum ability was firstly assessed by performing a maximum voluntary 
contraction (MVC) necessitating achieving a 100% contraction as verified by the 
LED display and also this was recorded on the graph master in the scanner control 
room for reference purposes. Two points were then used during the exercise phase 
which were staged at 70% and 90% of their (MVC) and highlighted by red and green 
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arrow markers on the display.  Detailed instructions were given and a test period was 
used for familiarisation purposes to ensure all participants were aware of the protocol 
and the exercise requirements, which were in time with a beeper at pre set intervals 
for the duration of the scan. This ensured that each participant performed all the 
required exercises to the same exertion levels of 70% and 90% of their individually 
assessed MVC, and for the same number of repetitions in order to ensure the validity 
of the results obtained. 
 
The exercise rig structure in figure 2.9, used for the quadriceps muscle studies with a 
curved phosphorus 
31
P RF coil mounted on the anterior quadriceps muscle and the 
NIRS light guides again mounted laterally.  A strap across the abdomen prevents 
abdominal muscles contributing to the force generated, as there is a tendency for 
subjects to tilt their pelvis in order to assist in generating additional force as muscle 
tiredness increases towards the end of the exercise periods. 
 
A voice intercom was used to instruct all volunteers to ensure safety and comfort, 
and an alarm was also hand held so that each participant could alert the scanner 
operator should they wish to stop the study. A visual display was also available in the 
control room to observe participants during the exercise element of the study. Figure 
2.10 shows the final position in the scanner this is with the volunteer fully enclosed 
with the head only protruding; individuals who became claustrophobic could not 
tolerate this and were unable to proceed with the scan. Individuals with known 
claustrophobia were differed at the initial screening stage to avoid this happening at 




2.19 Points used for measurement 
Magnetic resonance spectroscopy (MRS) offers a non-invasive window on cellular 
metabolism in vivo. The main techniques used in vivo are phosphorus 
31
P MRS, 
which yields information about energy turnover and proton handling, combined with 
near-infrared spectroscopy (NIRS), an optical technique which reports muscle 
oxygenation (Kemp & Radda, 1994).  
 
Figure 2.11 Points for assessment diagram, showing peaks representing inorganic 




P MRS spectrum from human quadriceps muscle, showing the fit 
generated by jMRUI, the software used to quantify the peaks. As previously stated 
initially the subject was asked to do a maximum voluntary contraction (MVC) in 
order to ascertain their 100% value, following which they exercised for a number of 
repetitions in time with a timed beeper at 90% of their maximal contractile force 
followed by a rest period after which the process was repeated at 70% of MVC. 
 
Initially after a series of scans to shim the magnet and obtain the best spectra form, 8 
resting spectra were obtained this scan lasting 1.1 minute followed by the acquisition 
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of 33 spectra over 3.1 minutes at 90% MVC. This was followed by 39 spectra being 
obtained during 5.2 minutes of recovery. During the second phase of exercise at 70% 
MVC 15 spectra were obtained over a two minute period, after which during the 
second recovery phase 39 spectra were then obtained over a 5.2 minute period. 
 
 
Figure 2.12 Monitor showing two wave forms of exercise repetition which represent 
leg extension effort and timing, this allowed for a visual check to be made at the data 
acquisition stage. 
 
As in figure 2.12, a graph was viewed and recorded in the control room to ensure the 
subjects accuracy and timing of the exercise repetitions in time with an electronic 
beep. Each exercise effort being initiated following an audible sound and held for the 
prescribed time. PCr rate constant was used to assess mitochondrial degradation and 
recovery kinetics; this was calculated manually by assessment of the spectra acquired 
following the scan. The spectra obtained at base line during the initial resting period 
and after each exercise period were checked on the monitor following the scan to 
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check on data acquisition and subject compliance with the protocol. 
 
 
Figure 2.13 Monitor showing PCr baseline top left of the screen and depletion after 
exercise at 70% top right and lastly bottom left after exercise at 90% of MVC.  
 
Figure 2.13 shows the top left hand box represents PCr at rest, the top right hand box 
represents data acquired immediately after exercise at 70% of maximum voluntary 
contraction (MVC) and the bottom left after exercise at 90% of MVC, the level of 
depletion can be clearly seen. In all 128 spectra were recorded with two recovery 
periods between the two exercise efforts. This was to allow wash out periods at the 
end of the two data acquisitions. This also allowed for a recording of recovery time 
and monitoring of the return period to the initial base line measurements, total scan 





Figure 2.14 PCr depletion and recovery peaks in this post scan check differ in screen 
placement from the previous figure 2.13, with the base line peaks being top left, after 
exercise at 70% of MVC the peaks can be now be seen bottom left, top right the 
peaks are representative of PCr depletion after exercise at 90% of MVC 
 
2.20 Patients 
Seventeen patients with known NAFLD and 18 age and BMI matched controls were 
studied using these protocols. Within the NAFLD group there was 11 males and 6 
females, in the control group we had 7 males and 11 females. 
 
2.21 Statistical analysis 
The primary outcome variable for the present study was the PCr recovery rate 
constant k. Groups were compared using the two-sample Student’s t test or Mann–
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Whitney U tests if distributional assumptions were not met following logarithmic or 
Box–Cox transformation. To assess the sensitivity of some of the results to the 
gender imbalance between groups, we also compared groups using linear 
regression/analysis of covariance (ANCOVA), adjusting for sex. Poisson’s 
regression was used to compare the number of metabolic components between 
groups. Spearman’s correlation coefficient (rs) was used to describe the strength of 
association between continuous variables. Statistical significance was delimited as 
P<0.05. Data are presented as means [95%confidence intervals (CIs)], unless stated 
otherwise, and exact P values are cited (values of P of ‘0.000’ provided by the 































The two groups (patients with NAFLD and control subjects) were well matched with 
no significant differences in age, total body weight, body mass index or percentage 
body fat mass (Table 3.1). Despite this matching of weight, BMI and total adiposity, 
the patients with NAFLD had a significantly greater waist circumference 108.6± (9) 
versus controls 100.8±(11.8) indicating increased central obesity. There were a 
greater proportion of males in the NAFLD group while there were a greater 
proportion of females within the control group (Table 3.1). Cardio respiratory fitness  
VO2peak measured as (ml/kg/min), even when normalized to total body weight did not 
differ significantly between the two groups. 
 
3.2 MRI scanning and determination of body composition 
In total, 35 individuals were studied this included 17 individuals with known 
NAFLD 11 males and 7 females and 18 controls, 8 males and 10 females. 
 
3.3 Magnetic resonance spectroscopy 
Table 1 demonstrates a marked difference in liver fat between the two groups with 
the NAFLD group having a liver fat of 24.8±2% vs. 2.21.5% in the control group. 
However IMCL in both the soleus and tibialis anterior was not significantly different 
between NAFLD and control individuals (Figure 3). 
 
3.4 Biochemical characteristics and components of the metabolic syndrome 
Patients with NAFLD had a significantly higher ALT but AST and GGT were not 
significantly different (Table 1). Although total cholesterol was not significantly 
different, patients with NAFLD had a significantly higher triglyceride and lower 
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HDL cholesterol. Fasting glucose concentrations did not differ significantly between 
the two groups. The prevalence of metabolic syndrome was greater in the NAFLD 
group (n=13, 76 % vs. n=5, 28%) and the patients with NAFLD had a higher mean 
number of components of the metabolic syndrome (Table 1). 
 
3.5 MR-derived measures of body composition  
Total abdominal fat did not differ between NAFLD patients and controls although 
when this depot was subdivided into subcutaneous and visceral fat, there was clearly 
a greater proportion of visceral fat in patients with NAFLD (Table 1). As expected, 
liver fat was higher in NAFLD patients but IMCL fat in both soleus and tibialis 
anterior was not significantly different between the two groups (Figure 3).  
 
3.6 Assessment of muscle mitochondrial function 
There were no significant differences in resting muscle intracellular pH (pHi) or 
phosphate metabolite ratios between the two groups. There was no significant 
cytosolic acidification during exercise in either group. The post exercise PCr 
recovery rate constant (a measure of muscle mitochondrial function in vivo) did not 
differ significantly between the two groups.  
 
3.7 Skeletal muscle pH and phosphorus metabolites 
Resting muscle intracellular pH between the two groups showed no significant 
difference and also there was no significant acidification during exercise in either the 
NAFLD or control group. Resting phosphate metabolic ratios of inorganic 
phosphate: ATP and PCr: ATP also did not differ between the two groups and there 
was no significant difference in the amount of PCr depletion during the exercise 
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protocol at either 70% or 90% of MVC. 
 
3.8 Relationship of muscle mitochondrial function with the metabolic syndrome (MS) 
and the number of MS components  
Comparing the two groups according to the presence (n=18) or absence (n=17) of the 
metabolic syndrome, we were not able to detect any significant difference in the PCr 
recovery rate constant with a difference of 0.04 (k min
-1
). Similarly, when we 
examine the number of components of the metabolic syndrome in both controls and 
NAFLD patients we found no correlation (r=-0.03, P=0.83).  
 
3.9 Correlation of muscle mitochondrial function with biochemical and body 
composition measurements  
There were no significant correlations between PCr recovery constant and age, 
weight, BMI, fat mass, VO2 peak, any biochemical measure or any MR-derived 













Table 3.1 Baseline characteristics of participants (mean +/- SD). 
 NAFLD (n=17) Controls 
(n=18) 
P 
Age (y)≠ 47 (41,52) 47 (34,51) 0.68 
Gender (M,F) 11 (65%),   




Weight (kg) 96.1 (14.8) 85.6 (15.7) 0.05 
BMI (kg/m
2
) 31.5(3.4) 30.53(5.24) 0.5 
% fat mass≠ 40.5 (30.1,44.1) 34.2 (29.2,44.8) 0.69 
Waist circumference (cm)≠ 108.6 (9) 100.8 (11.8) 0.03 
Systolic blood pressure≠
 
 125(120,140) 123.5(120,132) 0.62 
Diastolic blood pressure≠ 82(78,88) 75(70,80) 0.03 
Biochemical    
AST (mU/l)≠ 24(9.5,42.5) 21(16,25) 0.37 
ALT (mU/l)≠ 61 (30,83) 21 (16,32) 0.001 
GGT (mU/l)≠ 48(42,79) 28(23,40) 0.03 
Cholesterol (mmol/l)≠ 5.9(5.1,6.1) 5.2(4.7,5.7) 0.54 
HDL≠ 1(.9,1.2) 1.2(1.1,1.5) 0.007 
Triglyceride (mU/l)≠ 2.3(1.6,3.4) 1.3(1,2.3) 0.007 
Fasting glucose (mmol/l)≠ 5(4.7,5.3) 4.85(4.4,5.1) 0.18 
Metabolic syndrome (MS)    
Number with MS  13/17 (76 %) 5/18 (28 %) 0.004 
Components of MS
†
 2.9 ± 1.0 1.8 ± 1.2 0.05 
Cardio respiratory fitness    
V02 peak (ml/kg/min)≠ 23.5(20,31.3) 25.75(22.9,30) 0.69 
V02 peak/weight (ml/min)≠ 0.3(0.2, 0.3) 0.3(0.2, 0.4) 0.14 
Muscle 
31
P MRS*     
Resting Pi/ATP≠ 0.56 (0.49, 0.63) 0.44 (0.38, 0.58) 0.09 
Resting pH
†
 7.08 (7.06, 7.09) 7.08 (7.06, 7.10) 0.39 





Resting PCr/ATP 4.25±0.68 4.07±0.57 0.4 











1.62 (0.34, 1.86) 1.50 (1.18, 1.77) 0.81 
Values are means±S.D, medians (lower quartile, upper quartile) or frequency (%). 
*Pairs of results represent 70%/90% MVC (maximal voluntary contraction) 







3.10 Body composition data 
Body composition data demonstrating total abdominal fat, abdominal subcutaneous 
(SC) fat, visceral fat, intramyocellular fat (IMCL) of soleus and tibialis anterior 
muscles, liver fat and the number of components of the metabolic syndrome in 
patients with NAFLD (n=17) and age and BMI-matched controls (n=18). 
 
Figure 3 Body composition data above figures represent results of body fat, 






Figure 3.1 Phosphocreatine (PCr) recovery rate constant results, k (min
-1
) in patients 
























































Figure 3.2 Relationship between PCr rate constant, k (min
-1
) and the number of 
components of the metabolic syndrome within the controls (    ) and patients with 
NAFLD (   ). 
 
 
3.11 Results overview 
We have provided evidence that mitochondrial function in skeletal muscle is 
maintained in patients with NAFLD, in comparison to controls that are age, BMI and 
fitness matched, and cannot account for high disposition of fat or the increased 
prevalence of the metabolic syndrome. As a consequence of the findings of this study 
it would appear that there are additional factors other than skeletal muscle 
dysfunction that have a role in the phenotype of NAFLD. Available data suggests 


























In this study we set out to determine the oxidative capacity of skeletal muscle by 
investigating PCr recovery kinetics in the quadriceps muscle of NAFLD patients and 
age, BMI and cardio respiratory fitness matched controls. Although the phenotype of 
the NAFLD patients was found to be characterized by a disproportionately greater 
accumulation of liver and visceral fat coupled with increased components of the 
metabolic syndrome, compared to the controls, the rate of PCr recovery was similar 
between the control and NAFLD groups. The NAFLD group within this study from 
our results was not associated with any increase in intramyocellular lipid (IMCL), 
which has been linked with insulin resistance and muscle mitochondrial dysfunction 
in other studies (Toledo et al., 2008; Smith & Adams, 2011). Similarly, we did not 
observe any relationship between the components of the metabolic syndrome and the 
PCr rate constant, there also was not any observable difference in the PCr rate 
constant between those with and without the metabolic syndrome as found within 
this study. 
 
4.2 Role of skeletal muscle 
The data reported in this study suggests that defects in muscle mitochondrial function 
may occur later perhaps as a consequence rather than a cause of increased lipid 
deposition and associated metabolic syndrome, which has been supported in a 
number of other studies (Pessayre, 2008). Impaired oxidative phosphorylation by 
skeletal muscle mitochondria have been postulated to contribute to age-associated 
insulin resistance and fat accumulation within skeletal muscle (Short et al., 2005a). 
This impaired mitochondrial functional capacity in ageing has also been attributed to 
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a reduced mitochondrial content, as reflected by lower mtDNA content (Petersen et 
al., 2003).  
 
The aging process in humans begins around the age of 40 when muscle mass 
(sarcopenia) and strength gradually begin to decline at a rate of just under 1% per 
year. The process is caused by a decreased capacity for oxidative phosphorylation in 
the muscles (Menshikova et al., 2006). Given the strong evidence linking 
mitochondria dysfunction with aging, insulin resistance and T2DM, it is important to 
more precisely define specific loci of these defects. The focus of this study was to 
explore the possibility that deficiencies in muscle mitochondrial function plays a role 
in the aetiology of NAFLD, but we found no association with any increase in 
intramyocellular lipid (IMCL), and the rate of PCr recovery was similar between the 
control and NAFLD groups.  
 
Perhaps more importantly further research should aim to determine whether clinical 
interventions including exercise, diet and lifestyle changes may help correct these 
insufficiencies (Menshikova et al., 2006). Physical activity is reported to protect 
against sarcopenia and preserve mitochondrial function the origins of sarcopenia 
although common is poorly understood, oxidative stress and reduced mitochondrial 
function are thought to play a part (Short et al., 2005b). To what extent mitochondria 
are involved in the ageing process and reduction in muscle mass is controversial, a 
lot of the decline in the mitochondrial oxidative capacity may be more linked to a 




As PCr recovery (k min
-1
) was similar between the control 1.50 (1.18, 1.77) and 
NAFLD 1.62 (0.34, 1.86) groups, the defects that later cause a reduction in 
mitochondrial function may well be due to elements of the metabolic syndrome and 
insulin resistance, as well as due to ageing in general. As a consequence of these 
other metabolic defects, dysfunction of muscle mitochondria does not appear to be a 
major contributor to muscle fat accumulation liver disease and insulin resistance as 
explored within this study. This may be associated with an insulin resistance in 
muscle which occurs at a later point within the disease process were unused energy is 
stored as fat in the liver. It suggests that this may be linked to the insulin signalling 
cascade in association with increased intra myocellular lipid accumulation at a later 
time in the disease process and may  also be dependent on the severity of NAFLD 
and intra-hepatocellular lipid accumulation (Young & Leighton, 1998). 
 
As obese people have a reduced capacity to oxidize fatty acids as fuel compared with 
lean people during exercise, and because fatty acids are oxidized in the mitochondria, 
research into other mitochondrial defects may well be of value in the search for an 
explanation for this problem. In other animal studies it has been found that there is 
evidence that hepatic mitochondrial dysfunction precedes the development of 
NAFLD and insulin resistance in the hyperphagic, obese OLETF rat and in this study 
it was also documented that a progressive loss of mitochondrial function in 
conjunction with the transition from insulin resistance to T2D potentially contributes 
to NAFLD progression (Rector et al., 2010). These researchers also looked at the 
relationship between hepatic mitochondrial dysfunction and the link with hepatic 
steatosis and resistance to insulin and the potential role in any progression of 
NAFLD using OLETF rats. The results of this study raised the possibility that 
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mitochondrial dysfunction can be a cause, effect or a concurrent feature in the 
development of NAFLD (Rector et al., 2010). Our study set out to explore if there is 
any involvement of skeletal muscle mitochondrial function in the development of 
NAFLD. However our results indicate that mitochondrial function, which was 
determined via 
31
P-MRS measurements of the quadriceps muscle were similar after 
exercise in both groups. Moreover this similarity in the function of the mitochondria 
was apparent despite higher levels of liver fat and more elements of the metabolic 
syndrome. There was also no correlation with aerobic fitness as measured by V02 
peak (ml/kg/min), the NAFLD group results being 23.5 (20,31.3) versus the controls 
25.75 (22.9,30). However this could be due to a relatively small range of 
cardiorespiratory fitness that we observed in both groups within the study. 
 
In other studies it has been found that skeletal muscle mitochondria dysfunction has 
been linked as one of the main features of T2DM and that exercise enhances 
mitochondria electron transport chain activity in older human skeletal muscle, 
particularly in subsarcolemmal mitochondria, which is likely related to the 
concomitant increases in mitochondrial biogenesis (Menshikova et al., 2006). 
However the mechanisms of the pathogenesis of resistance to insulin and its link 
with diabetes have as yet to be clarified and therapeutic approaches like the effects of 
exercise and lifestyle changes are of general interest as potentially useful treatment 
modalities for NAFLD, and are worthy of further investigation. 
 
4.3 Role of adipose tissue 
In looking at treatments for metabolic diseases that are linked to obesity, a greater 
understanding of the origin and development of adipose tissue is therefore relevant to 
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any analysis.  It was previously thought that adipocytes were inert cells with a single 
function of lipid storage, however it is now known that they have a number of other 
functions including sensitivity to insulin, they also have an ability to secrete 
adipocyte specific endocrine hormones which have a regulatory effect on energy 
homeostasis within other tissues within the body (Stephens, 2012). Leptin is one 
such example which has inspired investigation among obesity researchers. Studies 
have shown that the hormone can rewire part of the brain that regulates appetite, 
future studies may shed new light on how metabolism goes awry in obesity and the 
importance of gaining more data on adipose tissue and its actions. 
 
Adipocytes are therefore known to be involved in the development of a number of 
metabolic diseases including the metabolic syndrome. Some studies have looked at 
the development of adipocytes from precursor cells and the proteins associated with 
this, with the possibility of the development of adipocyte development inhibitors. 
 
In a recent study by Rosen which revealed a new zinc finger protein Zfp 521 in the 
process of predipocyte differentiation and the ability of this to mediate its inhibitory 
effects on adipocyte development, future work within this area may be of value in 
obesity management (Stephens, 2012). 
 
4.4 Role of liver 
The mitochondria are important in hepatocyte metabolism, playing a role in the 
oxidation of fatty acids and oxidative process of phosphorylation (Hagopian et al., 
2005). Other mitochondrial dysfunctions within the body causes a decreased capacity 
to oxidise fatty acids, increases the transport and delivery of free fatty acids into the 
89 
 
liver and augmented hepatic fatty acid syntheses are thought to play a role in the 
pathogenesis of NAFLD.  This raises the point that mitochondrial abnormalities have 
such a part in the development of the disease that NAFLD is in fact a mitochondrial 
disease (Parsons & Green, 2011). 
 
4.5 Assessment of PCr depletion and recovery 
For our study we used a gold standard method to investigate muscle mitochondrial 
function that was safe and non-invasive facilitated by the use of MRS to assess PCr 
depletion and recovery, as was collecting data on total body fat using whole body 
MRI and intramyocellular and hepatocellular lipids by MRS. A positive element of 
our study has been that we did not find that skeletal muscle mitochondrial function 
was part of the aetiology of NAFLD which we initially suspected would be the case. 
More generalised mitochondrial disease caused by dysfunctional mitochondria 
within other systems of the body may be the link in the pathogenesis of the 
development of the metabolic syndrome and NAFLD.  
 
4.6 Study limitations 
A limitation of this study was that we focused only on the role of skeletal muscle 
mitochondrial dysfunction in the aetiology of NAFLD. We could also have looked at 




MRS or other methods, such as metabolite analysis of blood and urine or muscle 
biopsy allowing biochemical examination within our study subjects. Areas of 
weakness within this study have been the gender imbalance as within the NAFLD 
group (n=17) there were 11 males versus 6 females so a 65% male bias, whilst in the 
control group (n=18) there was 7 males versus 11 female a female bias of 61%. This 
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may have weakened the data on the prevalence of central adiposity and its link with 
the metabolic syndrome within this study. 
 
It was intended to include data on measures of insulin resistance e.g. HOMA-IR, but 
unfortunately this data set was incomplete at the time of writing. This or even data 
from oral glucose tolerance tests, would have been of use in determining differences 
in insulin sensitivity between the two groups within the study. The gold standard for 
investigating and quantifying insulin resistance is the hyperinsulinemic euglycemic 
clamp. This could have also been used within the study, but would have posed issues 
for volunteers time and added greatly to their commitment to an already busy study 
protocol. 
 
4.7 Conclusions and realisation of aims 
NAFLD, which is characterized by lipid deposition effecting greater than 5% of 
hepatocytes, has an association with the metabolic syndrome. This we found to be 
the case within our study as our results indicated that participants with NAFLD had 
thirteen out of seventeen (76%) 2.9 ± 1.0 more components of the metabolic 
syndrome compared to controls who had five out of eighteen (28%) 1.8 ± 1.2. It has 
been suggested that an impairment within the skeletal muscle in mitochondrial 
function may be a contributory factor to ectopic fat accumulation within the liver 
(Johannsen et al., 2012). 
 
The outcomes from this study indicates that the PCr rate constant k (min
-1
) is broadly 
similar between the controls and the subjects with NAFLD, which suggests that 
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skeletal muscle mitochondrial function is preserved in subjects with NAFLD.  We 
also found that  IMCL were not elevated in the NAFLD group versus controls. 
 
There was also no link between the subjects with the metabolic syndrome and their 
PCr rate constants, k (min
-1
) results or the number of components of the metabolic 
syndrome within the age and BMI matched controls and patients with NAFLD. We 
aimed to determine total body fat, which as was expected was higher in the NAFLD 
group who had a % fat mass of 40.5 (30.1,44.1) compared to controls 34.2 
(29.2,44.8). Liver fat which was determined by MRS, this in the NAFLD group was 
24.8±2% were as in the controls it was  2.21.5% , but as stated  previously we did 




































5.1 Future directions 
The results of this study in investigating the role of skeletal muscle mitochondrial 
function in the aetiology of NAFLD, suggests that the problem does not arise in 
skeletal muscle. However there could be other defects in muscle that were not 
detected by our methods. Biochemical measures of mitochondrial proteins, enzyme 
activities and lipids are often used as markers of mitochondrial content and muscle 
oxidative capacity, whereas we used 
31
P MRS spectrum from human quadriceps 
muscle to assess mitochondrial function. Therefore, future directions for this study 
may focus upon sites other than skeletal muscle e.g. liver or adipose tissue 
mitochondrial dysfunction in the aetiology of NAFLD. 
 
Progress in understanding the pathogenesis of NAFLD has lead to a greater 
understanding of the disease, however the primary metabolic issues that lead to lipid 
accumulation within the hepatocytes remains poorly understood. Due to the fact that 
mitochondria are critical metabolic organelles and that there is evidence indicating 
that any hepatic mitochondrial dysfunction is critically linked to the pathogenesis of 
NAFLD, this is therefore an area worthy of further investigation. In order to further 
our study, an investigation of hepatic mitochondrial function and its association with 
NAFLD and insulin resistance would be of value, as there are a number of 
methodologies to facilitate this. It would be of interest to investigate hepatic 
mitochondrial function by obtaining 
1
H MR spectra from the liver. Other relevant 
tests would be to investigate insulin resistance by hyperinsulinemic euglycemic 
clamp and see if there are any improvements in individuals along with reductions in 
liver fat in conjunction with an exercise and diet restriction regime, as a potential 
treatment modality.  
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Although all participants were age and BMI matched the control group in this study 
had a BMI of 30.53 (SD 15.7) versus the NAFLD group BMI 31.5 (3.4). A non 
diseased control group would therefore have been a positive addition to this study, as 
both groups studied were in the obese category. A further group with normal BMI of 
<25 would have been a useful addition. 
 
5.2 Factors relating to adipose tissue 
Adipocytes are involved in the maintenance and balance of energy storage and 
expenditure, therefore any impairment of mitochondrial activity could predispose 
individuals to obesity, a reduction in mitochondria biogenesis has also been linked. 
This perhaps highlights the important role of mitochondria and its associated 
complications with disease and obesity in any dysfunctional state. To further this 
study adipose tissue could therefore be an area of investigation into the effects of 
mitochondrial dysfunction within this tissue in the aetiology of NAFLD. Target areas 
in looking at obesity and its associated complications could involve looking at white 
and brown adipose tissue mitochondria and exploring any relationship between 
dysfunction and obesity and other associated complications, such as insulin 
resistance. This could facilitate more understanding on what potential treatments 
targeting adipose tissue and their mitochondria that may have benefits to increase 
oxidative capacity within these tissues. 
 
Obesity is a condition in which an excess of adipose tissue results in a positive 
energy balance, a metabolic disorder which is increasing in most societies. There are 
a number of clinical problems that can be associated with this which include cancers, 
atherosclerosis and an increased risk of T2DM. In looking at treatments for 
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metabolic diseases that are linked to obesity, a greater understanding of the origin 
and development of adipose tissue is therefore relevant to any analysis. It was 
previously thought that adipocytes were inert cells with a single function of lipid 
storage, however it is now known that they have a number of other functions 
including sensitivity to insulin, they also have an ability to secrete adipocyte specific 
endocrine hormones which have a regulatory effect on energy homeostasis within 
other tissues within the body (Stephens, 2012).  
 
5.3 Vitamin D 
Vitamin D has been shown to have an involvement in muscle contraction and energy 
levels, recent research has shown that muscle function can be improved with 
supplements of this vitamin (Sinha et al., 2013). In a study conducted at Newcastle 
University, Sinha used non-invasive MR scans in a cohort of 12 patients with muscle 
fatigue and severe deficiency of vitamin D in order to measure their response to 
exercise. Apart from the well documented effects on bone health, fatigue within 
muscle is a symptom of vitamin D deficiency which was postulated within this study 
to be due to a reduced efficiency of the muscle mitochondria and to explore any link 
with vitamin D. In line with our methodologies, this research team used 
31
P MRS of 
muscle, but using the calf muscle instead of the quadriceps to measure 
phosphcreatine recovery times as a measure of mitochondrial function, shorter 
recovery times being linked with improved mitochondrial function. 
 
The results of this small n=12 study found that there was an improvement after the 
group  took oral supplements of vitamin D for a period of just 10-12 weeks. It was 
reported that the PCr recovery half time improved from the base line figure of 34.4 
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seconds to 27.8 seconds with a concomitant improvement in fatigue symptoms. 
Using a parallel study it was demonstrated that there is a link between vitamin D and 
mitochondrial function. According to Sinha this data suggests that vitamin D may 
modulate mitochondrial energy transduction. This may represent the bioenergetic 
basis for the fatigue experienced by vitamin D deficient adolescents and adults, 
although further studies are required to establish causality.  
 
As understanding of the many functions of vitamin D has grown the presence of 
vitamin D deficiency has become more evident within Western populations, as has 
NAFLD as the most common cause of chronic liver disease. NAFLD and vitamin D 
deficiency are often found together although there are similar associations with 
sedentary lifestyle and obesity, there is also evidence to a closely linked and 
potentially causative relationship between deficiency of vitamin D and NAFLD 
(Kwok et al., 2013). We could have added this to our study and obtained vitamin D 
levels from blood samples, to see if there was any link with low levels and skeletal 
muscle mitochondrial dysfunction and NAFLD. 
 
5.4 Ageing and Sarcopenia 
Physical activity is reported to protect against sarcopenia and preserve mitochondrial 
function the origins of sarcopenia although common is poorly understood; oxidative 
stress and reduced mitochondrial function are thought to play a part. To what extent 
mitochondria are involved in the ageing process and reduction in muscle mass is 
controversial, a lot of the decline in the mitochondrial oxidative capacity may be 
more linked to a lack of physical activity and disease rather than age in itself (Waters 
et al., 2009). It is likely that a decline in muscle mass and strength with a decline in 
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endurance capacity causes this reduction in physical activity which is then followed 
by this loss of muscle. This reduction in muscle mass which is responsible according 
to Waters for 30% of resting energy expenditure and protein turnover, as well as 70% 
body cell mass. Physical activity levels that can be attributed to this account for a 
decrease in energy expenditure and increase the prevalence of obesity in older age 
groups, in particular abdominal fat accumulation. Alterations such as these in body 
composition can be linked to insulin resistance and the development of T2D and 
other metabolic abnormalities such as hyperlipidemia (Waters et al., 2009). 
 
Muscle weakness can lead to reduced muscle mass, but a reduction in ATP 
production may according to Waters also decrease endurance and muscle strength. 
This may be linked to mitochondrial DNA oxidative damage due to ageing, which 
with any cumulative effect may explain any overall reduction in mitochondrial DNA 
(Waters et al., 2009) and have a further effect muscle strength.  
 
5.5 Nutritional issues and NAFLD 
Certain natural nutrients are also known to have strong anti-inflammatory properties 
and have been shown to be of value in the treatment of NAFLD. These include 
Vitamin E (Tocopherol) and omega 3 fatty acids. Vitamin C is also known to react 
with reactive oxygen species (ROS) blocking the propagation of radical reactions in 
a wide range of oxidative stress situations, but the potential therapeutic efficiency of 
the use of antioxidants in NAFLD is not fully understood. Most human studies have 
been limited, as they have been retrospective and therefore relied on diet recall 
within the groups studied. This being self reported could have weakened these 
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studies, therefore larger investigations may be of value in establishing causal 
relationships between certain nutrients and NAFLD.  
 
In a study that induced fatty liver disease in Wistar rats it was found that vitamin C 
reduced oxidative stress and inhibited the development of liver steatosis. Whilst in 
the other group, vitamin E did not prevent development of fatty liver disease nor did 
it reduce oxidative stress as observed within this study (Oliveira et al., 2003). There 
is therefore evidence to suggest a role for dietary antioxidants, oxidative stress which 
is said to be caused by an imbalance between the harmful oxidants and protective 
antioxidants, but further research is warranted. These being diet derived or 
endogenous, and occurs in patients with NAFLD due to increased lipid oxidation 
(Browning & Horton, 2004). 
 
As Hippocrates said, “let food be thy medicine and medicine be thy food”, this area 
maybe worthy of further investigation as to casual impacts of diet and the potential 
benefits of nutrients in patients with the metabolic syndrome and NAFLD. 
 
Certain diets may have a positive effect in the prevention and treatment of certain 
characteristic traits of NAFLD. Low fat high fiber vegetarian diets have had positive 
effects on cardiovascular disease and diabetes in certain clinical trials, but this diet 
has not been evaluated in NAFLD. These diets do typically cause weight loss and 
can lower the blood lipids that contribute to NAFLD, similar diets have also been 
associated with a reduction in insulin resistance which is a known symptom of 
NAFLD and greater antioxidant protection in comparison with omnivorus diets (Kuo 
et al., 2004; Videla et al., 2006). An addition to this, it has been demonstrated that 
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accumulation of iron aggravates insulin resistance and associated oxidative stress. As 
plant based diets have somewhat less bioavailability of iron vegetarians therefore 
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7.1 Publications arising from the thesis, with abstracts 
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not mediated by impaired mitochondrial oxidative phosphorylation in skeletal 
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Poster Presentation 
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Poster presentation 
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7.2 MRS methods Shimming 31P Protocol 
Press view make sure adjust volume on is ticked. Move green grid box over area of 
interest, click options- Adjustments, click go Click Options-Adjustments-Frequency- 
Press go until difference =0’HZ then Click apply. 
Go to 3D Shim tab at bottom of screen, click standard, then click measure , calculate 
then apply (bottom of 2 options) after shim has stopped 
Then into interactive shim then click measure, if you can’t see left hand edge of peak 
click A1to move peak to the right. Full Width half maximum, lowest number 
possible to be achieved by adjusting X, Y & Z axis using (+) or (-) icons. Press stop 
then apply. 
Go back into Frequency then press go until number difference is =0’HZ, press apply 
then close. 
Back to main screen click apply to start. 
When Spectra available click the fid icon then right click in spectrum window then 
go to parameters, enter 0 to 10 for width then check for any splits. Back to exam then 
drag last series down to copy then in dialogue box click Manual, change parameters 
to 2000 and averages to 32 then click apply. 
Set up Meas. System by CTRL Escape to access advanced user, then type meduser1 
then click CTRL escape, then click run, then select MstartMate. Follow instructions 
on sheet then close. Windows Explorer. Go to 192.168.2.3 (Q), click on Sims-meas-





7.3 Data save 
Click on Spectroscopy and on main screen to highlight box in blue go to options 
export raw data. File C/temp, Andrew store x2 spectroscopy label as fully relaxed 
(FR) and 32 Averages (32avg). For 128 exercise need to follow meas.out and 
meas.asc protocol. Press Control, escape, Windows Explorer, My computer, Med 
system C, Temp File-Andrew. 
 
To archive to disc, enter disc, then click transfer to DVD in patient browser, check 
bottom of screen accepted, open DVD to check when completed (in patient browser). 
To transfer to memory sticks go into My Computer click on192.168.2.3(Q)Then 
click on Temp, then Andrew then rename meas files with patient code, then copy and 




























7.4 Exercise Protocol, 128 MRS Spectra  
 
90%of MVC 
 Start instructions at spectra 6, to ensure exercise starts at spectra 9. 
 Begin instructions at spectra 30, to ensure exercise stops at end of spectra 32. 
 
70% of MVC 
 Start instructions at spectra 70, to ensure exercise starts at spectra 73. 
 Begin instructions at spectra 86, to ensure exercise stops at end of spectra 88. 
 




































7.5  Extract from participant Information Sheet 
 
 
Fatty Liver Disease and Blood Vessel Function 
(Endothelial function and structure in patients with Non-Alcoholic   
Fatty Liver Disease) 
 
Study 1: Observational Study (NAFLD Patient/Healthy Control). 
 
Invitation to participate 
You have been invited to participate in a research project. However, before you 
decide whether or not you wish to participate, it is important that you understand 
why you are doing it and what it will involve. Please take time to read this 
information sheet carefully and be sure to ask any questions you have, and if you 
wish, discuss it with friends, relatives or your GP. We will do our best to explain and 
to provide any further information you may ask for now or later. You do not have to 
make an immediate decision with regards to whether you wish to take part in the 
study.  
 
Background to research area of interest 
Non-alcoholic fatty liver disease (fatty liver disease) results in an inflamed fatty liver 
and, if left untreated, over many years can sometimes progress to cirrhosis (the 
replacement of liver tissue by scar tissue) and very occasionally liver failure. Fatty 
liver disease is thought to be largely explained by the additional weight carried in 
certain individuals and the associated insulin resistance.  
 
Insulin resistance occurs when the response to the hormone insulin is blocked in 
different tissues in the body (skeletal muscle, fat tissue and liver). As a result of this, 
higher than normal amounts of insulin are required to exert its effects. Insulin 
resistance is a main contributor in causing type 2 diabetes.  
   
Insulin is involved in regulating blood flow. The flow of blood to our limbs, organs 
and skin is altered during various circumstances (e.g. exercise) to maintain vital 
functions in the body. The response of the body is a marked widening of the arteries; 
this response increases the flow of blood to the limbs, organs and skin. A reduction 
in the ability of the arteries to widen is one of the contributory factors of 
cardiovascular disease such as high blood pressure, stroke and heart attack. We are 
interested in how insulin resistance alters the ability of blood vessels to widen. We 





Why have I been chosen? 
You have been invited to participate in this study as a patient that has been diagnosed 
with fatty liver disease, or as a healthy individual (control).  The object of the study 
is to get a better understanding of the role of insulin resistance in causing fatty liver 
disease and its effect on heart function. 
 
Do I have to take part?  
Your participation in the study is entirely voluntary. If you decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. You 
can withdraw from the study at any point without having to give a reason and 
without affecting your future medical care or relationship with the medical staff 
looking after you. 
 
What does the study entail?  
Now that you have expressed interest in this study we have provided the following 
information. Following this, if you agree to participate in the study, you will be 
invited to attend the University Hospital Aintree (UHA) to undergo some 
physiological tests. The tests we propose are for research purposes and will take 
approximately 2 hours of your time at the University Hospital Aintree. This was 
previously known as Fazakerley Hospital. 
 
The researcher will meet you at a predetermined time at the Clinical Sciences 
Building, at the University Hospital Aintree. This is the large white building located 
between the Accident and Emergency Department and the Walton Centre for 
Neurology and Neurosurgery (green building).  
 
We will ask you to undergo the following tests: 
 
(A) Blood Sample: (10 minutes) 
10 mls of blood will be taken for liver function and lipid profile tests.  
 
(B) MRI scan: (1 - 2 hours)  
This will take place at the MARIARC (Magnetic Resonance and Image Analysis 
Research Centre) Centre on Pembroke Place immediately behind the Royal 
Liverpool University Hospital in the city centre at a pre-determined time (see map).   
You will be asked to attend the Unit having fasted from the night before and not 
performed strenuous physical activity for 2 days beforehand.  You will be weighed 
and the fat distribution in your body will be measured using magnetic resonance 
scanning. Your body dimensions will also be measured.  
Firstly, the staff at the MARIARC will ask you to fill in a short safety screening form 
to make sure there are no reasons why you would not be suitable for magnetic 
resonance scanning. You will be asked to wear a gown (changing rooms are 
provided) and remove items which are affected by the magnetic field (e.g. hearing 
aids, mobile phones, keys, coins, pens, credit cards (secure lockers are provided). 
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While inside the scanner, you will be asked to wear earplugs to protect your hearing 
from the noise of the scanner. This visit involves you having a scan of your whole 
body to determine how much fat is present and specifically how much is present 
within your liver and muscle. During your scans you will be asked to carry out some 
leg exercises, this will allow us to assess your leg muscle and its recovery following 
a period of rest. 
 
 (C) Echocardiography Examination (ECHO) (1 hour) 
Heart size, structure and function will be assessed using echocardiography. This will 
involve an ultrasound scan (on the chest) and the attachment of ECG electrodes to 
measure heart rate. 
 
(D) Fitness Test (30 minutes) 
The researcher will assess your fitness level. You will be asked to bring with you a 
pair of trainers and suitable clothing to exercise on a treadmill. Briefly, you will be 
required to walk on a motorised treadmill where the speed and treadmill increment 
will be increased every 2 min until you choose to end the test. This will measure the 
amount of work you perform at increasing grades of difficulty. Oxygen uptake will 
be measured breath−by−breath using an online gas analyser. This procedure will 
require you to wear a facemask connected to the gas analyser. Heart rate will also be 
measured so you will be required to wear a chest strap, which will transmit heart rate 
data to a monitor which is similar to a watch worn around the wrist. 
 
What are the possible disadvantages of taking part?  
Magnetic Resonance Scanning. The scan is very safe involving no x-ray exposure 
and without side effects. We will ask a radiologist (a specialist doctor in reading scan 
images) to review the scan images to ensure there are no abnormalities. Occasionally 
we may find abnormalities within the abdomen. Almost always these are of no 
medical or clinical significance but sometimes will require further inspection or 
evaluation. If we find any such abnormalities we will write to your GP and inform 
them of the abnormalities and ask them to refer to an appropriate specialty for further 
investigation.  
 
What are the benefits of taking part? 
Although by taking part in this study you will gain no direct benefit, the information 
gained from these measurements will help us to gain a greater understanding of fatty 
liver disease, its effect on the heart, and assist us to design more effective treatment 
strategies in the future for all patients with this condition.  Additionally, if we do 
identify a health problem that requires further medical attention, for example, high 
blood pressure, we will explain this to you, and inform your GP for further 
management. 
 
What expenses will I receive? 




You will be given a copy of the information sheet and a signed consent form to 
keep.      
























































7.7  Ethical approval 
 
Liverpool (Adult) Research Ethics Committee 






 Telephone: 0151 330 2077  
Facsimile: 0151 330 2075 
23 March 2009 
 
Dr Daniel Cuthbertson 
Clinical Senior Lecturer and Honorary Consultant Physician 
University of Liverpool 
Clinical Sciences Centre, 





Dear Dr Cuthbertson 
 
Full title of study: Endothelial function and structure in patients with Non-
Alcoholic Fatty Liver Disease (NAFLD). 
REC reference number: 09/H1005/7 
 
Thank you for your letter of 28 February 2009, responding to the Committee’s 





The further information has been considered on behalf of the Committee by the 
Chair.  
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for 
the above research on the basis described in the application form, protocol and 
supporting documentation [as revised], subject to the conditions specified below. 
 
Ethical review of research sites 
 
The Committee agreed that all sites in this study should be exempt from site-specific 
assessment (SSA).  There is no need to complete Part C of the application form or to 
inform Local Research Ethics Committees (LRECs) about the research.  The 
favourable opinion for the study applies to all sites involved in the research 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the 
start of the study. 
 
Management permission or approval must be obtained from each host organisation 
prior to the start of the study at the site concerned. 
 
Management permission at NHS sites (“R&D approval”) should be obtained from 
the relevant care organisation(s) in accordance with NHS research governance 
arrangements.  Guidance on applying for NHS permission is available in the 
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Response to Request for Further Information  
  
  28 February 
2009   
 
 
C.V. for Supervisor   
  
  30 September 
2008   
 
 
Participant Consent Form  
  
2  28 February 
2009   
 
 
Participant Information Sheets for study 1 and 
study 2   
2 -  28 February 





2  28 February 
2009   
 
 
Questionnaire: Validated  
  
      
  
Statistician Comments  
  
1  17 December 









2009   
 
Investigator CV  
  




2.0  09 January 2009   
  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard 
Operating Procedures for Research Ethics Committees in the UK. 
 
After ethical review 
 
Now that you have completed the application process please visit the National 
Research Ethics Website > After Review  
 
You are invited to give your view of the service that you have received from the 
National Research Ethics Service and the application procedure.  If you wish to make 
your views known please use the feedback form available on the website. 
 
The attached document “After ethical review –guidance for researchers” gives 
detailed guidance on reporting requirements for studies with a favourable opinion, 
including: 
 
 Notifying substantial amendments 
 Progress and safety reports 




The NRES website also provides guidance on these topics, which is updated in the 
light of changes in reporting requirements or procedures. 
 
We would also like to inform you that we consult regularly with stakeholders to 
improve our service. If you would like to join our Reference Group please email 
referencegroup@nres.npsa.nhs.uk. 
 
09/H1005/7 Please quote this number on all correspondence 
 
 











Enclosures: “After ethical review – guidance for researchers”  
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